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Abstract
Immune-induced activation of the hypothalamic-pituitary-adrenal (HPA) axis elevates
glucocorticoids, anti-inflammatory hormones, promoting the effective resolution of
inflammation. Psychological stress can modulate this anti-inflammatory mechanism, but the
mechanisms underlying this modulation remain largely unknown. The immune-induced HPA
axis activation is, in large part, mediated by prostaglandin E2 (PGE2), an inflammatory
mediator. In the brain, PGE2 attenuates GABAergic synaptic transmission onto corticotropinreleasing hormone (CRH) neurons in the paraventricular nucleus of the hypothalamus (PVN)
that act as the apex of the HPA axis. The removal of GABA-mediated inhibition (i.e.
disinhibition) excites CRH neurons and, consequently, activates the HPA axis. Here, we
examined the modulatory effects of psychological stress on this PGE2-mediated synaptic
mechanism for HPA axis activation. To this end, we used whole-cell patch clamp
electrophysiology to record GABAergic synaptic transmission onto PVN-CRH neurons as
changes in the amplitude of evoked inhibitory post-synaptic current (eIPSCs). We contrasted
findings in acute brain slices from mice that have been stressed by restraint (psychological
stress) with those of naïve (non-stressed) mice. We first confirmed that, in slices from naïve
mice, PGE2 potently depressed GABAergic synaptic transmission to PVN-CRH neurons. On
the other hand, in slices from stressed mice, PGE2 had heterogeneous effects, potentiating some
synapses in addition to depressing others. Using receptor subtype-specific agonists and
antagonists, we showed that the EP3 subtype of the PGE2 receptor mediated the synaptic
depression by inhibiting the release of GABA from the pre-synaptic terminals in naïve slices.
On the other hand, the EP2 and EP4 receptors mediated the potentiation of GABA release from
the pre-synaptic terminals. Acute stress did not alter these mechanisms for bidirectional
synaptic plasticity. By contrast, a blockade of EP1 receptor mimicked the effects of stress,
shifting the balance of depression and potentiation toward potentiation. We conclude that EP 1
receptor suppresses EP2 and EP4-mediated pre-synaptic potentiation (thus making EP3mediated depression dominant) and that psychological stress blocks this EP1-mediated
mechanism. We propose that psychological stress modulates the interplay between different
subtypes of EP receptors to ultimately contribute to altering the immune-induced activation of
the HPA axis.
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Chapter 1
1 Introduction
1.1 Overview
Threats to homeostasis, either real or anticipated, trigger a wide array of highly coordinated
behavioral and physiological changes to defend or re-establish homeostasis (Bains,
Wamsteeker Cusulin, & Inoue, 2015; Johnson, Kamilaris, Chrousos, & Gold, 1992) – this
response is collectively termed the “stress response” (Chrousos, 2009). A major regulator of
stress response is the activation of the hypothalamic-pituitary-adrenal (HPA) axis, resulting
in an elevation of glucocorticoids (GCs) in circulation. GCs act throughout the periphery and
in the brain to mediate various changes associated with the stress response, including the
feedback inhibition of the HPA axis. In addition to this rapid response, an important aspect of
HPA axis activation is that the response is highly plastic and undergoes long-term changes in
its function. In other words, prior stress exposures change the responsiveness of the HPA axis
to future stressors. This plasticity enables organisms to fine-tune their response to their
dynamic environment. However, such flexibility also makes the system susceptible to
dysregulation, resulting in maladaptive changes. For example, excessive stress has been
linked hypo- and hyper-sensitivity of the HPA axis (Chrousos & Kino, 2007; Faravelli et al.,
2012; Ogawa et al., 1994). The mechanisms underlying the flexibility of the HPA axis are
complex and remain largely unknown. The general goal of my M.Sc. thesis is to investigate
neural mechanisms that contribute to the plasticity of the HPA axis. Specifically, this thesis
examines the neural mechanisms involved in the activation of the HPA axis in response to
inflammation (one type of stressor) and how these mechanisms are altered by prior stress
exposure. To this end, this M.Sc. thesis focused on one type of synapses terminating on a
population of neurons in the hypothalamus that initiates the HPA axis and examined 1) how
these synapses respond to inflammatory signals, and 2) how they change their responsiveness
to an inflammatory signal following stress exposure.

1.2 The stress response
The stress response is the collective set of responses of the body to stimuli that disrupt or
threaten homeostasis. Stress response causes a range of psychological and physiological
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changes, including heightened alertness, suppression of appetite, sleep, and reproductive
drive, as well as increased heart rate, respiratory rate, blood pressure, and metabolism
(Chrousos, 2009; Griffin, 1990; Smith & Vale, 2006). The stress response is primarily
adaptive, however, when in excess, the stress response can have detrimental consequences.
Chronic stress has been correlated with physiological conditions like Type II diabetes,
obesity, and hypertension (Chrousos, 2009; Elenkov & Chrousos, 1999;) as well as to
psychiatric disorders such as panic attacks, anxiety, and depression (Chrousos, 2000;
Contarino et al., 1999; Hammen, Kim, Eberhart, & Brennan, 2009; Johnson et al., 1992;
Pervanidou & Chrousos, 2010; Yehuda, Giller, Southwick, Lowy, & Mason, 1991). Given its
connection to pervasive diseases and mental disorders, it is important to understand how the
brain regulates the stress response.

1.3 The HPA axis
1.3.1 Composition of HPA axis
The main neuroendocrine mediator of the stress response is the HPA axis. The HPA axis is
composed of a hormonal cascade involving the hypothalamus, the anterior pituitary and the
adrenal cortex (Figure 1-1). Corticotropin-releasing hormone (CRH) neurons in the
paraventricular nucleus of the hypothalamus (PVN) form the apex of the HPA axis. The cell
bodies of these neurons are clustered in the medial parvocellular subdivision of the PVN.
These neurons send projections to the median eminence, a part of the hypothalamus that is
integral to the hypophyseal portal system. The median eminence lacks the blood-brainbarrier. Thus, CRH released from axonal projections in the median eminence enters the
portal circulation to reach the anterior pituitary. At the anterior pituitary, CRH binds to the
CRH type 1 receptor (CRHR1) on corticotroph cells. CRHR1 stimulation triggers the
transcription of the pro-opiomelanocortin (POMC) gene; a precursor polypeptide that will be
enzymatically cleaved into adrenocorticotropic hormone (ACTH) and other peptides like βendorphins. ACTH will then be released from the anterior pituitary into the systemic
bloodstream (Stalla, Stalla, Loeffler, von Werder, & Müller, 1987). ACTH binds to
melanocortin type 2 receptors (MC2-R), a Gαs coupled receptor and stimulates the synthesis
and release of GCs from the zona fasciculate of the adrenal cortex (Herman et al., 2016;
Smith & Vale, 2006). GCs, the ultimate output of the HPA axis, are distributed throughout
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the body via the general circulation and induce an array of psychophysiological changes
associated with the stress response. GCs also exert negative feedback regulation over the
HPA axis by decreasing the production of CRH and ACTH.
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Hypothalamus

PVN

CRH

Anterior pituitary gland

ACTH

GC

Adrenal
cortex

Figure 1-1: Schematic of the HPA axis.
Corticotropin-releasing hormone (CRH) is secreted from neurons of the paraventricular
nucleus of the hypothalamus (PVN). In turn, CRH cause the anterior pituitary gland to
secrete adrenocorticotropic hormone (ACTH). ACTH causes the adrenal cortex to secrete
glucocorticoid (GC) for negative feedback regulation of the HPA axis.
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1.3.2 Actions of GCs
GCs are a class of steroid hormones. They are essential for normal life as they regulate or
support physiological processes in the cardiovascular, metabolic, immune and other systems.
For example, GCs cause increased cardiac output, energy metabolism through glucose
mobilization, increased cerebral blood flow, vasoconstriction and immune modulation
(Sapolsky, Romero, & Munck, 2000; Smith & Vale, 2006).
GCs act via two receptors: mineralocorticoid receptor (MR) and glucocorticoid receptor
(GR) (de Kloet, Joëls, & Holsboer, 2005). MRs are expressed in many tissue/cell types of the
body, including the kidneys, heart, brown adipose tissue, and sweat glands. By contrast, GRs
are ubiquitous. In the CNS, MRs expression is predominantly restricted to the lateral septum
and hippocampus, while GR expression is ubiquitous across brain areas and cell types,
including stress-related brain regions like the hippocampus, the prefrontal cortex, the
amygdala and the PVN (Herman et al., 2003; Reul & de Kloet, 1985). Like other steroid
hormone receptor family members, MRs and GRs are ligand-dependent transcription factors
that act in the nucleus. Non-liganded MRs/GRs are found in the cytoplasm as large oligomers
with heat shock protein (HSP)s. When GC binds MR or GR, it activates the receptor by
releasing the HSP. The activated GR or MR binds hormone response element (HRE)s, a
receptor-specific DNA-binding site associated with hormone-regulated genes, that alter
transcription (Guyre, 1998). Corticosterone (CORT), the major GC in rodents, is bound with
six- to ten-fold greater affinity by MRs (Kd = 0.5 nM) than GRs (Kd = 2.5-5 nM) (Reul & de
Kloet, 1985). In other words, MRs are occupied by low levels of GCs. MRs were 80%
occupied by a 1 mg/100 g (subcutaneous) body weight dose of CORT. On the other hand,
50% occupation of GRs required doses of 50-100 mg/100 g body weight (Reul & de Kloet,
1985). Given its occupation at the baseline and relative lack of further occupation by stressinduced increases in GC, it has been proposed that MR signaling plays a role in preparing the
body for the initiation of the stress response (when the concentration is low) (de Kloet et al.,
2005; Finsterwald & Alberini, 2014). The lower affinity of GRs allows for differential
binding at the basalth(low GC) and stress-induced conditions (higher concentrations of GCs).
This difference in GCs binding to GRs after stress drives the stress response.
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With relevance to the plasticity of stress response, GRs are implicated in the formation and
consolidation of aversive memory by modulating plasticity mechanisms in brain areas such
as the hippocampus and amygdala (Finsterwald & Alberini, 2014; Lupien, Maheu, Tu,
Fiocco, & Schramek, 2007). The memory of stress, in turn, modifies future stress response
(de Kloet et al., 2005; Lupien et al., 2007; Yuen et al., 2009). GC activation of GRs also
mediates negative feedback regulation of the HPA axis by suppressing production of CRH
and ACTH in the PVN and the anterior pituitary, respectively (Smith & Vale, 2006; Tasker
& Herman, 2011). Thus, GRs serve a vital role in terminating the HPA axis stress response
(Herman, McKlveen, Solomon, Carvalho-Netto, & Myers, 2012). GRs can mediate the
strength of negative feedback to influence the magnitude of HPA axis activity (de Kloet &
Reul, 1987; van Haarst, Oitzl, & de Kloet, 1997).

1.4 Regulating activation of HPA axis
The activity of the HPA axis is influenced by a wide range of external and internal signals,
which are integrated by the neural circuits, ultimately converging on the PVN. While there
are many different modalities of stress, they are broadly categorized as physiological or
psychological. It is generally believed that different modalities of stressors recruit distinct
neuronal circuits reaching to the PVN to deploy a common stress response, the activation of
the HPA axis (Figure 1-2) (Bains et al., 2015).

1.4.1 Physiological stress
Physiological stress is a real disturbance to homeostasis (Dayas, Buller, Crane, Xu, & Day,
2001). Physiological stressors include inflammation, hypoxia, pain, starvation,
hypoglycemia, and hyper-/hypo-thermia (Colaianna et al., 2013; Price, 2000). A major
neuronal pathway for physiological stressors to activate the HPA axis is relayed by the brain
stem nuclei. Specifically, catecholaminergic (adrenergic and noradrenergic) cell groups in the
nucleus of solitary tract and the ventrolateral medulla send direct, monosynaptic projections
to the PVN (Herman & Cullinan, 1997; Ulrich-Lai & Herman, 2009). The activation of these
adrenergic and noradrenergic inputs are essential for the activation of the HPA axis following
various physiological, but not psychological, stress (Buller, Xu, Dayas, & Day, 2001; Li,
Ericsson, & Sawchenko, 1996).
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1.4.2 Psychological stress
Psychological stress is a perceived threat to homeostasis that is not associated with physical
disturbances (Dickerson & Kemeny, 2004). Psychological stressors include predator odor,
novel environment, social isolation and social conflict among conspecifics (Pruessner et al.,
2010). Despite the lack of physical changes in bodily parameters, psychological stress
likewise activates the HPA axis.
Psychological stress recruits cortico-limbic structures including the prefrontal cortex,
hippocampus, and amygdala to signal through hypothalamic (e.g. dorsomedial hypothalamus
(DMH)) and peri-hypothalamic nuclei (e.g. bed nucleus of stria terminalis (BNST)) to the
PVN (Flak, Solomon, Jankord, Krause, & Herman, 2012; Ulrich-Lai & Herman, 2009). It
was proposed that this signaling pathway is “multi-layered” meaning that it has intercepting
structures between the brain areas involved such that it has “processing anticipatory” (Bains
et al., 2015). This implies that previous stress information can be stored, in the forms of
synaptic and neural plasticity after stress (Bliss & Collingridge, 1993; Foy, Stanton, Levine,
& Thompson, 1987; Schwabe & Wolf, 2012). Stored information from previous stress
exposure could modify the subsequent stress response, leading to sensitization or
desensitization to future stressors.
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Figure 1-2: Neuronal circuitry involved in signaling physiological and psychological
stressors to activate the HPA axis.
Physiological stress (blue) acts through the brainstem nuclei of the ventromedial medulla
(VM) and the nucleus of the solitary tract (NTS) that send direct catecholaminergic,
monosynaptic projections (solid black arrows) to the paraventricular nucleus of the
hypothalamus (PVN). This neuronal pathway is necessary for the activation of the
hypothalamic-pituitary-adrenal (HPA) axis in response to systemic inflammation, a
prototypical physiological stressor (Herman & Cullinan, 1997; Ulrich-Lai & Herman, 2009).
Psychological stress (red) has “multi-layered” processing involving the corticolimbic
structures (prefrontal cortex [PFC], amygdala, hippocampus) and hypothalamic (dorsomedial
hypothalamus [DMH]) and peri-hypothalamic structures (bed nucleus of stria terminalis
[BNST]) that signal to the PVN. This pathway is believed to play major roles in the
activation the HPA axis in response to restraint stress, a psychological stressor (Flak et al.,
2012; Ulrich-Lai & Herman, 2009).
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1.4.3 Converging physiological and psychological stress
modalities
As discussed above, different types of stressors converge to activate the HPA axis. This
convergence suggests the possibility for interactions between different modalities of stress
(Bains et al., 2015). For example, it has been shown that tail shock stress 1 day prior to
systemic inflammation sensitized the activation of the HPA by the inflammation (Johnson et
al., 2002). By contrast, it has also been shown that 7 days of twice daily 10-minute restraints
attenuated HPA axis activation by an inflammation trigger (Gadek-Michalska, Spyrka, &
Bugajski, 2005). However, it remains largely unexplored how one type of stressor modifies
the subsequent response to a different stressor, particularly stressors of different modalities.
This thesis investigates the interactions between two modalities of stress: a physiological
stressor and a psychological stressor. I will identify how the synaptic mechanisms for
inflammation (physiological stressor)-induced HPA axis activation can be modulated by a
prior exposure to immobilization stress (psychological stressor).

1.5 Anti-inflammatory regulation by GCs
Inflammation is a response primarily mediated by the immune system, which protects our
body from injury and infection (Barton, 2008; Nathan, 2002). The inflammatory response
involves coordinated immunovascular responses that deliver immune agents (Newton &
Dixit, 2012) to eliminate the infection and repair the injury (Barton, 2008). While generally
pro-survival, unregulated (or excessive) inflammation can have adverse consequences.
Unregulated inflammation can include prolonged (chronic) or exaggerated inflammation
implicated in various disease conditions including atherosclerosis, rheumatoid arthritis, and
sepsis (Barton, 2008; Elenkov & Chrousos, 1999; Hench, Kendall, Slocumb, & Polley,
1949). Therefore, inflammation needs to be tightly regulated. One of the signals regulating
inflammation is GCs. In addition to their stress-related actions, GCs are potent antiinflammatory mediators. Thus, immune-induced activation of the HPA axis provides a
critical negative feedback regulation for the resolution of inflammatory response.
GCs can modulate gene expression for immuno-suppressive and anti-inflammatory actions in
many ways. GCs, via GR binding, block the transcription factor activator protein-1 (AP-1)
from binding to its target pro-inflammatory genes. Similarly, GRs bind to the transcription

10
factor nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) and prevent it
from binding to DNA to initiate transcription of pro-inflammatory cytokines. GCs binding to
GRs also increases the synthesis of NFκB inhibitor alpha (IκBα). GRs also negatively
regulate mRNA stability of various pro-inflammatory cytokines (Guyre, 1998; Ruzek,
Pearce, Miller, & Biron, 1999).

1.6 Peripheral inflammation mechanism of signaling to affect
CNS
Peripheral inflammation initiates when cells of the immune system such as tissue
macrophages and monocytes recognize inflammatory stimuli, such as the bacterial endotoxin,
lipopolysaccharide (LPS), via surface-expressed pattern recognition receptors (Aderem &
Ulevitch, 2000; Alexander & Rietschel, 2001; Medzhitov & Janeway, 2000). Activated
innate immune cells then secrete cytokines and other inflammatory mediators that spread the
inflammatory signals to the body and/or further recruits other immune cells to the site of
inflammation (adaptive immune response) (Galic, Riazi, & Pittman, 2012). Inflammation
originating peripherally can be sensed by the CNS by multiple pathways including the vagal
afferents, circumventricular organs (which lacks the blood-brain-barrier [BBB]), and through
the BBB (Blatteis, 2007; Ransohoff, Kivisäkk, & Kidd, 2003).
In response to the afferent inflammatory signals, the CNS initiates the an overlapping
inflammatory response in the CNS, including synthesis of pro-inflammatory cytokines (Layé,
Parnet, Goujon, & Dantzer, 1994; Pyter, Pineros, Galang, McClintock, & Prendergast, 2009;
Quan, Stern, Whiteside, & Herkenham, 1999; Riazi et al., 2008; Rothwell, Luheshi, &
Toulmond, 1996; Turrin et al., 2001). One of the major downstream mediators of this
cytokine cascade is prostaglandin E2 (PGE2) (Ricciotti & FitzGerald, 2011), which is
synthesized by endothelial and perivascular cells (Morimoto, Murakami, Nakamori, Sakata,
& Watanabe, 1989; Rivier & Vale, 1991). This thesis will focus on PGE2 as it is the final
signaling molecule for the activation of the HPA axis via CRH neurons.

1.7 PGE2 and the neuroendocrine stress response
PGE2 is a highly studied mediator initiating the immune-induced activation of the HPA axis
(Morimoto et al., 1989; Rivier & Vale, 1991). PGE2 and other PGs are signaling molecules
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made by oxidizing 20 carbon polyunsaturated fatty acids derived from phospholipids
comprising the cellular membrane. Specifically, PGE2 is synthesized from the 20 carbon
polyunsaturated fatty acid of arachidonic acid. Arachidonic acid is cleaved from membrane
phospholipids by phospholipase A2. Cyclooxygenase (COX) enzymes convert arachidonic
acid into PGH2. There are two subtypes of the COX enzyme: COX-1 (constitutive) and
COX-2 (inducible). COX-1 is the dominant source of PGs for housekeeping functions, such
as gastric epithelial cytoprotection and homeostasis, while COX-2 serves to synthesize PGs
triggered by stimuli, such as in response to growth factors or in proliferative diseases like
cancer; both COX can contribute to PG release during inflammation (Dubois et al., 1998).
PGH2 is converted into many different PGs by specific synthases (Kalinski, 2012; Narumiya,
Sugimoto, & Ushikubi, 1999). PGE2 is synthesized from PGH2 by prostaglandin E synthase.
Several prostaglandin E synthases have been identified, but to date, microsomal
prostaglandin E synthase-1 (mPGES-1) emerges as the key enzyme for the creation of PGE 2
in the brain during inflammation (Elander et al., 2009).

1.8 PGE2 receptors
PGE2 can act by binding to at least four different G-protein-coupled receptors (GPCR)
termed E prostanoid (EP) receptor: EP1, EP2, EP3, and EP4 (Furuyashiki & Narumiya, 2009;
Sugimoto & Narumiya, 2007). The four PGE2 receptors have different G-protein α subunits.
EP1 receptor signals via Gαq and increases intracellular calcium (Ca 2+) level which can
influence vesicle release (Narumiya et al., 1999; Woodward, Jones, & Narumiya, 2011). EP2
and EP4 receptors are each linked with Gαs which activates adenylate cyclase (AC) to
increase the levels of cyclic adenosine monophosphate (cAMP) in the cells. cAMP
subsequently allows activation of protein kinase A (PKA) that acts on cAMP response
elements binding proteins (CREB) in order to exert its effects (Narumiya et al., 1999). EP3
receptors are primarily coupled with Gαi/o in the PVN, which decreases the level cAMP (in a
manner opposite that of Gαs). Interestingly, EP3 receptor, through Gβγ, has been shown to
mobilize intracellular Ca2+ (Hatae, Sugimoto, & Ichikawa, 2002; Zhang et al., 2011;
Furuyashiki & Narumiya, 2011).
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Figure 1-3: PGE2 receptors subtypes include: EP1, EP2, EP3, EP4.
All four types of EP receptors are G-protein coupled receptors (GPCR). The Gαi/o-coupled
EP3 receptor suppresses adenylate cyclase (AC) and decrease the creation of cyclic adenosine
monophosphate (cAMP). cAMP typically activates protein kinase A (PKA) to act on cAMP
response binding elements (CREB) (Hatae, Sugimoto, & Ichikawa, 2002; Zhang et al., 2011).
By contrast, Gαs-coupled EP2 and EP4 receptors activate AC to increase cAMP and thus act
on CREB (Narumiya et al., 1999). Gαq-coupled EP1 receptor increases intracellular calcium
(Ca2+) which affects vesicle release and activates protein kinase C (PKC) which regulates EP
receptors (Narumiya et al., 1999; Woodward, Jones, & Narumiya, 2011; Furuyashiki &
Narumiya, 2011).
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The EP receptors are distributed widely throughout the body (Figure 1-3). For example, in
rodents EP1 receptor is located in the papillary collecting ducts of the kidney, lungs, stomach,
and thalamus, while in humans its location is restricted mast cells, pulmonary veins,
keratinocytes, myometrium, and colon smooth muscle (Narumiya et al., 1999; Sugimoto &
Narumiya, 2007). This thesis focuses on the relevance of the EP receptors to the HPA axis
input, so it is important to elaborate on the presence of these receptors at and around the
PVN. EP1 mRNA expression has been shown in the PVN using in situ hybridization (Oka et
al., 2000). On the other hand, the PVN neurons do not express mRNA for EP3 (Zhang &
Rivest, 1999). Other studies showed that EP3 receptor protein is present in GABA axon
terminals on PVN neurons as demonstrated by immunohistochemistry in rat (Nakamura et
al., 2000) and supported by in situ hybridization identifying EP3 mRNA expression in nuclei
that send projections to the PVN (Ek, Arias, Sawchenko, & Ericsson-Dahlstrand, 2000). EP4
receptor mRNA has been localized to the PVN (Zhang & Rivest, 1999, 2000). The existence
of EP1, EP3, and EP4 receptors in PVN neurons or inputs support the findings that these
receptors might be involved in modulating the HPA axis response to inflammation. A clear
EP2 receptor localization is lacking from the literature, so it may or may not be present in the
PVN.
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1.9 PGE2 in inflammation
PGE2 is one of the most studied inflammatory mediators that activate the HPA axis.
Numerous studies showed that systemic administration of LPS or pro-inflammatory
cytokines, such as IL-1β and TNFα, induce COX-2 expression in the brain vasculature
(Breder & Saper, 1996; Cao, Matsumura, Yamagata, & Watanabe, 1996; Quan, Whiteside, &
Herkenham, 1998). Given that LPS and IL-1β were applied to the periphery, these data also
led to the view that circulating afferent inflammatory signals are transduced into PGE 2 at the
cerebral vasculature (García-Bueno, Serrats, & Sawchenko, 2009). In this view, due to its
small size and lipophilic properties, PGE2 diffuses into the brain to mediate the signaling
cascade in the CNS that ultimately activates the HPA axis (Schiltz & Sawchenko, 2002,
2003). In line with this idea, microinjection of exogenous PGE 2 directly into the rat
hypothalamus led to increased levels of the ACTH in the plasma (Katsuura, Arimura, Koves,
& Gottschall, 1990; Morimoto et al., 1989), further clarifying that it is PGE2 acting in
hypothalamus to activate the HPA axis.
The importance of PGE2 in inflammation-induced HPA axis activation is further supported
by pharmacological and genetic studies targeting PGE 2 synthesis and signaling.
Pharmacological inhibition of COX through application of indomethacin blocks the increase
in ACTH and CORT concentration induced by IL-1β (Parsadaniantz et al., 2000) or by LPS
(Matsuoka et al., 2003; Narumiya & Furuyashiki, 2011). Furthermore, mPGES-1 knockout
mice show a blunted elevation of ACTH and CORT release after systemic LPS (Elander et
al., 2009). HPA axis activation by systemic LPS has been shown to be completely abolished
in mice lacking either EP1 or EP3 receptor (Furuyashiki & Narumiya, 2009; Matsuoka et al.,
2003).
The neuronal mechanisms whereby PGE2 activates the HPA axis have only recently been
fully explored. PGE2 acts on the GABA synapses on the PVN-CRH neuron (Ferri &
Ferguson, 2003). So consequently, this thesis will next elaborate on the PVN, its CRH
neuron population, and the GABA afferents of the CRH neurons.
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1.10 The PVN
The PVN is the apex of the HPA axis, which is a structure that houses the synapses of focus
for this thesis. The PVN is a nucleus in the hypothalamus located bilaterally adjacent to the
dorsal tip of the third ventricle (Figure 1-4). In addition to neuroendocrine neurons that
release CRH, the PVN contain several other types of neuroendocrine neurons that regulate
metabolism, reproduction and osmotic balance, as well as non-neuroendocrine neurons that
control the autonomic nervous system. Thus, the PVN is widely regarded as the center for the
neuroendocrine and autonomic control (Swanson, Sawchenko, Rivier, & Vale, 1983).

1.10.1 Characterization of neuronal subtypes of the PVN
The PVN is composed of a diverse set of cell types corresponding to the diverse
physiological roles of the nucleus. These neuron types have been classified by their
morphological (i.e. size of their cell bodies), molecular (i.e. types of neuropeptide expressed)
(Biag et al., 2012; Herman et al., 2003; Liposits, 1993; Swanson et al., 1983; Ulrich-Lai &
Herman, 2009), anatomical (i.e. localization in the PVN subdivisions and their projection
targets) (Swanson & Kuypers, 1980), and electrophysiological properties (i.e. spiking
threshold) (Tasker & Dudek, 1991). The PVN also contains pre-autonomic neurons, which
are non-neuroendocrine neurons that send projections to the brainstem and spinal cord to
control the sympathetic tone (e.g. increase heart rate and blood pressure, regulate appetite)
(Stern, 2001; Swanson & Sawchenko, 1983). In addition to these projection neurons (i.e.
neuroendocrine and pre-autonomic neurons), the PVN contains a small population of
interneurons. Recent studies have shown this monosynaptic connectivity using viral tracing
and optogenetic circuit mapping (Jiang, Rajamanickam, & Justice, 2018). Yet, the local
targets of these neurons and their physiological functions remains largely unknown. Since the
different types of neurons can be classified by their distinct electrophysiological properties, a
“fingerprint” can be used to distinguish the subtype during patch-clamp electrophysiology
experiments (Luther, Halmos, & Tasker, 2000; Tasker & Dudek, 1991); this involves
observing the characteristic response of different neurons to a current clamp protocol of 10
pA stepwise depolarization (Figure 1-5 A). The three types of neurons present within the
PVN include: 1) magnocellular; 2) parvocellular; 3) pre-autonomic.
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1.10.1.1 Magnocellular neurons
Magnocellular neurons (MNC) are a group of neuroendocrine neurons that are characterized
by relatively large cell body size (diameter of ~ 20-30 μm in rats) and possessing two to three
sparsely branched primary dendrites oriented bidirectionally (Tasker & Dudek, 1991). MNCs
are present in the anterior, medial and posterior PVN (Swanson & Sawchenko, 1983). MNCs
project their axons to the posterior pituitary where hormones are stored and released directly
into the blood-stream (Benarroch, 2005; Tasker & Dudek, 1991). MNCs synthesize oxytocin
(OXY) (Hashimoto, Matsuura, & Ueta, 2014) and arginine vasopressin (AVP) (Berghorn,
Knapp, Hoffman, & Sherman, 1995; Dohanics, Hoffman, & Verbalis, 1996; Renaud &
Bourquet, 1991). OXY promotes suckling-induced milk ejection (Cunningham &
Sawchenko, 1991), uterine contractions during labour (Blanks & Thornton, 2003), the stress
response (Jezova, Skultetyova, Tokarev, Bakos, & Vigas, 1995; Piekut, Pretel, & Applegate,
1996; Wotjak et al., 1998), and regulates body fluid volume (Leng, Brown, & Russell, 1999).
AVP, also known as antidiuretic hormone (ADH), plays a major role in regulating the blood
osmolality and volume (and thus electrolyte homeostasis) in response to dehydration and
hypovolemia (Leng et al., 1999). During dehydration and hypovolemia, AVP acts on its
receptors expressed in the distal or collecting tubules of the kidney to promote fluid retention
by increasing water reabsorption and reducing urination (Aguilera & Rabadan-Diehl, 2000).
Electrophysiologically, MNCs exhibit a pronounced delay to the first action potential with a
transient outward rectification (Figure 1-5 B) in response to depolarizing current injection
(Tasker & Dudek, 1991). This delay to first action potential is mediated by A-type voltagegated potassium channels, as is evidenced by their sensitivity to 4-aminopyridine (a selective
blocker of members of Kv1 (Shaker) family of voltage-activated K+ channels) (Luther et al.,
2000).

1.10.1.2 Neuroendocrine parvocellular neurons
Parvocellular neurons are further classified into two neuronal subtypes based on their
projection targets: neuroendocrine parvocellular neurons (PNCs) and pre-autonomic
parvocellular neurons (PAs). PNCs are characterized by relatively small cell body size
(diameter of ~ 10-25 μm in rats) and more branched dendrites in a bidirectional orientation
(Tasker & Dudek, 1991). PNCs are present in the medial PVN (Luther et al., 2002; Swanson
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& Sawchenko, 1983). PNCs send projections to the median eminence (Stern, 2015). PNCs
synthesize and secrete anterior pituitary hormones including CRH, thyrotropin-releasing
hormones (TRH), and somatostatin (SS) (also known as growth hormone-inhibiting hormone
(GHIH)) (Ceccatelli, Villar, Goldstein, & Hökfelt, 1989; Pammer, Fodor, & Palkovits, 1988;
Stern, 2015). CRH, as described in section 1.3.1, serves as the start of the HPA axis signaling
to the anterior pituitary (Herman et al., 2003; Smith & Vale, 2006; Swanson et al., 1983).
TRH initiates the hypothalamic–pituitary–thyroid axis (Lechan & Fekete, 2006; Luther &
Tasker, 2000; Tasker & Dudek, 1991; Vale, Spiess, Rivier, & Rivier, 1981). GHIHs are best
characterized for their actions in inhibiting growth hormone secretion (Olias et al., 2004), but
also regulate the endocrine system, affect neurotransmission, cell proliferation, and inhibit
the release of insulin and glucagon (Unger, Dobbs, and Orci, 1978). PNCs, in contrast to
MNCs and PAs, are characterized by the absence of the prominent A-type K + conductance
and absence of the low-threshold T-type Ca2+ conductance (Figure 1-5 D) (Luther et al.,
2002).

1.10.1.3 Pre-autonomic parvocellular neurons
PA neurons are characterized by relatively small cell body size (diameter of ~ 11-25 μm in
rats) and radially oriented, multipolar dendritic arbors (Tasker & Dudek, 1991). PAs are
present in the dorsal and ventral PVN (Luther et al., 2002; Swanson & Sawchenko, 1983)
and send projections to the brainstem, specifically the caudal medulla, and spinal cord
autonomic control centers to regulate the autonomic functions (Luther et al., 2002; Stern,
2001). Some PA neurons express neuropeptides that are found in neuro-endocrine neurons
including CRH, OXY and AVP which act as neurotransmitters at the projection targets
(Kalsbeek et al., 2010; Müller et al., 2000). For example, OXY neurons that regulate gastric
reflexes; AVP neurons that are involved in regulating blood pressure, temperature, and
brown fat thermogenesis; and CRH neurons, which are involved in the autonomic response to
stress. PAs exhibit a short burst of large action potentials firing at a low threshold (Figure 15 C) in response to depolarizing current injection (Luther et al., 2002). Given that the lowthreshold potentials persisted in tetrodotoxin (TTX) but were blocked by solutions containing
low Ca2+ and Cd2+, this firing is due to T-type Ca2+ conductance (Tasker & Dudek, 1991).
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Figure 1-4:The distribution of different types of neurons in the PVN.
The PVN is composed of heterogeneous populations of neurons, including: corticotropinreleasing hormone (CRH) neurons, thyrotropin-releasing hormone (TRH) neurons, growth
hormone-inhibiting hormone (GHIH), tyrosine hydroxylase (TH) neurons, vasopressin
(VAS), oxytocin (OXY), and growth hormone-releasing hormone (GRH) neurons. Adapted
from (Simmons & Swanson, 2009).
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Figure 1-5: Electrophysiological properties of PVN neurons.
(A) Current clamp protocol for electrophysiological fingerprinting of PVN neurons. (B)
Magnocellular neurons (MNC) exhibit a delay to the first action potential (arrow) due to Atype K+ channel activation. (C) Parvocellular neuroendocrine neurons (PNC) lack the delay
or low-threshold spike. (D) Parvocellular pre-autonomic neurons (PA) have a low-threshold
spike (thick line) due to T-type Ca2+ channels (Luther et al., 2000; Luther & Tasker, 2000;
Stern, 2001).

20

1.11 GABA-mediated synaptic transmission on CRH neurons
PVN-CRH neurons receive many GABAergic inputs. Specifically, electron microscopy
imaging has identified that approximately half of the all synaptic terminals (46.2%) in the
medial parvocellular PVN, which contains CRH neurons, are GABAergic (Miklós & Kovács,
2002). This thesis will explore GABA function as it relates to the PVN-CRH neuron.

1.11.1 GABA is an inhibitory neurotransmitter
GABA, previously known as Factor Ι, was first identified for its action of inhibiting the
formation of a stretch receptor neuron impulse in crayfish (Elliott & Flow, 1956). GABA is
the major inhibitory neurotransmitter of the mammalian nervous system (Watanabe,
Maemura, Kanbara, Tamayama, & Hayasaki, 2002). A large portion, approximately one
sixth of all synapses, use GABA (Sheikh, Martin, & Martin, 1999; Somogyi, Tamás, Lujan,
& Buhl, 1998). GABA is synthesized from L-glutamic acid by the enzyme glutamic acid
decarboxylase (GAD). In mammals, GAD comes in two isoforms: GAD65 and GAD67, which
have different tissue and subcellular distributions and functions (Kaufman, Houser, & Tobin,
1991; Sheikh et al., 1999). Vesicular GABA transporter (VGAT) loads GABA into synaptic
vesicles. Synaptic vesicle exocytosis is caused by fusion machinery activated by elevated
levels of intracellular Ca2+ in synaptic terminals. Specifically, Ca2+-dependent
synaptotagmins activate soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein
receptor (SNARE)s to cause vesicle docking and fusion with the membrane. Ca2+ may be
elevated in the pre-synaptic terminal due to an action potential, which causes voltage-gated
Ca2+ channels to open and transiently increase the local Ca 2+ concentration at the presynaptic active zone (Südhof, 2012). Vesicle exocytosis causes the release of
neurotransmitter into the synaptic cleft where transmitter may diffuse to receptors. GABA
transporter (GAT) clears GABA neurotransmitter from the synaptic cleft in order to prevent
further action (Scimemi, 2014). Once re-uptaken, GABA is metabolized into succinic acid by
GABA transaminase (GABA-T) (Tao, Yuan, Tang, Xu, & Yang, 2006) and is then inactive.
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1.11.2 GABA receptors
As described previously, GABA exerts its neurotransmission actions through receptors. The
two classes of GABA receptor are: GABA A and GABAB, which differ in their
pharmacological, electrophysiological and biochemical properties (Olsen & DeLorey, 1999).
GABAA receptors are the main GABA receptor involved in fast synaptic transmission, so are
the focus of this thesis. GABAA receptors are present in the CNS, including the PVN-CRH
neurons as demonstrated by dual hybridization histochemistry (Cullinan, Ziegler, & Herman,
2008). GABAA receptor is a hetero-pentameric transmembrane protein that is composed of
subunits: α1-6, β1-3, γ1-3, δ, ε, θ, π, or ρ1-3 (Luscher, Fuchs, & Kilpatrick, 2011; Olsen &
DeLorey, 1999), where different subunits combinations provide different functions (Olsen &
Sieghart, 2009). GABAA receptors are ionotropic receptors, also known as ligand-gated ion
channels, which selectively conduct chloride (Cl-). GABAA receptors allow Cl- to flow across
the membrane and down its electrochemical gradient. In adult neurons, the low intracellular
Cl- compared to extracellular Cl- means GABAA receptors conduct influx of Cl- at the resting
membrane potential (i.e. -70 mV) which causes hyperpolarization of the post-synaptic
membrane (Olsen & DeLorey, 1999; Wu & Sun, 2015). Cl- will flow out of the cell if the
internal voltage is less than resting potential (i.e. -60 mV), and Cl- will flow in if it is more
than resting potential (i.e. -75 mV), hyperpolarizing the membrane, resulting in an increase in
the firing threshold and thus a reduction in the probability of action potential initiation,
causing neuronal inhibition. Increased Cl- permeability can depolarize a neuron under some
conditions of high intracellular Cl-, such as during development, which can instead excite the
neuron (Owens, Boyce, Davis, & Kriegstein, 1996).
GABAB receptors are found in the central nervous system and autonomic peripheral nervous
system. GABAB receptors are metabotropic receptors, also known as G-protein coupled
receptors, which are linked via a G-protein to potassium (K+) channels (Kaupmann et al.,
1998). GABAB receptors allow the flow of K+ across the membrane at more hyperpolarized
potentials, since the reversal potential of the GABAB-mediated inhibitory post-synaptic
potential (IPSP) is -100 mV (Gassmann & Bettler, 2012).
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1.11.3 Inhibition of GABA disinhibits PVN-CRH neurons to
activate the HPA axis
GABA-mediated inhibition tonically acts on PVN-CRH neuron excitability and as a
consequence constrains HPA axis activity (Cullinan et al., 2008; Makara & Stark, 1974).
Microinjection of the competitive GABAA antagonist, bicuculline, into rat PVN induced a
robust induction of c-Fos, an immediate early gene that informs a recent history of neural
activity, in medial parvocellular PVN (Cole & Sawchenko, 2002). This activation of PVN
neurons suggests their removal from tonic GABA-mediated inhibition. Another study by
Hewitt et al. reported that bicuculline microinjection into the PVN increased the circulating
corticosteroids, indicating that the release from the GABA-mediated inhibition leads to HPA
axis activation (Hewitt, Wamsteeker, Kurz, & Bains, 2009). Additionally, by using cellattached recordings, this study showed bath application of bicuculline increased the spike
activity of PNCs, suggesting that GABA typically inhibits their spiking (Hewitt et al., 2009).
The PVN neurons receive this tonic GABA-mediated inhibition originating from many brain
regions. Retrograde tracing and immunohistochemistry have identified the anterior
perifornical area (a region of the bed nucleus of stria terminalis), peri supra-optic area,
anterior hypothalamic, and dorsomedial hypothalamic nucleus as major origins of GABA
projections to the PVN (Cullinan et al., 2008; Roland & Sawchenko, 1993; Ulrich-Lai &
Herman, 2009).
While there is strong evidence, as described in section 1.9, that PGE2 plays a key role in the
activation of the HPA axis in response to inflammation (Morimoto et al., 1989; Rivier &
Vale, 1991), it was not until recently that the literature explored how this effect may be
achieved. PGE2 application during ex vivo electrophysiology patch clamp recording
increased the spike frequency of PNCs neurons, suggesting that PGE2 can excite putative
CRH neurons by locally acting at the PVN in slice preparation (Ferri & Ferguson, 2003;
Ferri, Yuill, & Ferguson, 2005). Application of the GABAA antagonist, bicuculline, into the
PVN mimicked PGE2-mediated excitation of the PNCs (Ferri et al., 2005). Given the known
tonic inhibition of PVN-CRH neurons, one possible mechanism suggested in the literature
whereby PGE2 could excite CRH neurons is to remove the GABA inhibition. These
observations suggest that PGE2 blocks GABAergic inputs onto PNCs and consequently
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activates HPA axis (Ferri & Ferguson, 2003; Ferri et al., 2005). Our group recently further
examined this mechanism and revealed that PGE 2 acts on pre-synaptic EP3 receptors to
depress the synaptic release of GABA onto PVN-CRH neurons (Khazaeipool, Wiederman, &
Inoue, 2018).

1.12 Rationale, hypothesis, aims
1.12.1 Rationale
The identification of a synaptic mechanism for inflammation-induced (i.e. PGE2-mediated)
activation of PVN-CRH neurons paved a way to investigate the potential neuronal mechanisms
for the integration of different stress information. That is, a number of in vivo studies have
shown that prior stress exposure causes lasting changes in the regulatory mechanisms of the
HPA axis, leading to hypo- and hyper-sensitivity of the neuroendocrine response to future
stressors (Chrousos & Kino, 2007; Faravelli et al., 2012; Ogawa et al., 1994). For example,
Johnston et al., demonstrated that 1, 4, and 10 days after a series of inescapable tail shocks
(average intertrial interval = 60 s), the CORT and ACTH response of male rats to systemic
LPS administration (10 μg/kg, intraperitoneal injection) significantly increased (Johnson et al.,
2002). Thus, this study demonstrated that exposure to one type of stressor, tail shock, can
sensitize the ACTH and CORT response to subsequent HPA activation by a different stressor
(inflammatory stress). On the other hand, a separate study found that 7 days of twice-a-day 10
min restraint stress prior to LPS-induced inflammation, attenuated the typical rise of in plasma
ACTH and CORT levels compared to control non-restrained male rats (Gadek-Michalska et
al., 2005). These studies indicate that, different types and paradigms of stress exposure can
bidirectionally change the responsiveness of the HPA axis to inflammatory stress. Building
upon our recent finding that GABAergic synapses onto PVN-CRH neurons are the target of
PGE2 (a key mediator of inflammatory stress), in this thesis we examined if and how prior
exposure to a different type of stressor (restraint stress) alter the responsiveness of these GABA
synapses to PGE2. Our use of restraint stress as the psychological stressor for this thesis most
closely resembles the modality of stress employed by Gadek-Michelska et al. (2005); so our
predictions align with their observation of an impairment of the inflammation-induced HPA
axis activation by prior restraint.
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1.12.2 Hypothesis
Prior acute restraint stress impairs the synaptic mechanisms for PGE 2-induced CRH neuron
disinhibition.

1.12.3 Aims
To test the hypothesis, my thesis has three aims:
Aim 1: To establish a mouse model to study the effects of PGE2 on GABA synapses onto
PVN-CRH neurons.
Previous studies by us and others that identified the actions of PGEs on GABAergic synapses
in the PVN used rats. The development of CRH-reporter mouse line (Cusulin, Füzesi, Watts,
& Bains, 2013) now allows us to visually identify CRH neurons for ex vivo patch clamp
electrophysiology experiments. This is a major advancement in the field, as prior rat studies
that form the basis of the rationale of this study (section 1.11.3) relied on the
electrophysiological characteristics of PNC neurons that include not only CRH but other
types of neuroendocrine neurons.
Prior stress exposure may alter the electrophysiological characteristics of PVN neurons
(Bittar et al., 2019; Senst, 2014), which could potentially introduce a sampling bias to
previous studies on the effects of stress on the PGE 2 actions in rats. Thus, I will first replicate
the effects of PGE2 on GABAergic synapses onto PVN-CRH neurons in stress-naïve mice.
Aim 2: To examine the impact of prior psychological stress on PGE2-mediated
attenuation of GABA synapse.
I will next explore the impact of psychological stress on the effects of PGE 2 on GABAergic
synaptic transmission onto PVN-CRH neurons.
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Aim 3: To examine synaptic mechanisms through which prior psychological stress alters
the PGE2-induced depression of GABA synapses on CRH neurons.
The effects of PGE2 on GABAergic synaptic transmission on CRH neurons of the PVN have
previously been identified as EP3-dependent (Khazaeipool et al., 2018). I will examine if
prior exposure to stress alters the EP3-mediated PGE2 action on GABA transmission on
PVN-CRH neurons. I will also examine if prior exposure to stress alters the functions of the
other EP receptors (EP1, EP2, and EP4) to change the overall effects of PGE2 on GABAergic
synapses onto PVN-CRH neurons (Figure 1-6).
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Figure 1-6: Schematic diagram identifying the hypothesized synaptic mechanism of
PGE2-induced activation of the HPA axis and its change after acute restraint stress.
(A) In naïve conditions, PGE2 activates the CRH neurons by depressing inhibitory GABA
synaptic transmission via pre-synaptic EP3 receptor. (B) After acute restraint stress, the
PGE2-mediated depression of GABA synapse is impaired via modulation of EP receptors.
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Chapter 2
2 Materials and Methods
2.1 Animal handling
All the experiments involving the use of animals were approved by the institutional care and
use committee of the University of Western Ontario in accordance with the guideline of the
Canadian Counsel on Animal Care. Experiments were performed using male adult (7-16
weeks old) CRH-reporter mice that express tdTomato red fluorescent protein in CRH
neurons (Cusulin et al., 2013). These CRH reporter mice are on a C57BL/6 background and
bred by crossing a homozygous CRH-IRES-Cre driver (Jackson Laboratories, stock #:
012704) and a homozygous Cre-dependent ROSA26-tdTomato reporter (Jackson
Laboratories, stock #: 007914) according to previous publications (Cusulin et al., 2013;
Salter, Sunstrum, Matovic, & Inoue, 2018) in the University of Western Ontario animal
facility. Animals were bred in a breeding facility in the campus and transferred to a housing
room at least 5 days prior to experimentation. The animals were kept in a 12 h/12 h light–
dark cycle (light on at 7:00 AM). Food and water were provided ad libitum. Mice were
housed in cages of 2 – 4 littermates. Mice were provided with a small, tinted, plastic shelter
for environmental enrichment.
Every effort was made to prevent causing any unnecessary distress to the animals including
minimizing handling. For the acute restraint stress experiments, mice were immobilized for 1
hour within a well-ventilated Falcon® 50 mL high-clarity polypropylene conical centrifuge
tube (Fischer Scientific, cat #: 1495949A). A small hole was cut into the cap of the Falcon
tube to allow the tail to protrude. A plunger was used to adjust the size of the tube to
accommodate differently sized mice in appropriate restraint (Figure 2-1). Acute restraint was
performed during the light phase, for 1 hour, between 9:00 AM and 12:00 PM. Immediately
after the end of immobilization stress, animals were deeply anesthetized with isoflurane for
decapitation and brain extraction. Animals not receiving acute restraint stress were
transferred directly from home cage to a chamber saturated with isoflurane for decapitation.
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Figure 2-1: Cartoon schematic of a mouse in restraint stress.
7

The mouse is sufficiently restrained in the Falcon® 50 mL high-clarity polypropylene conical
centrifuge tube using a plunger (orange), if necessary, based on its size to hold it in place.
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2.2 Slice preparation and maintenance
The brain was quickly removed and immersed into ice-cold slicing solution containing (in
mM: NaCl 87, KCl 2.5, NaHCO3 25, CaCl2·2H2O 0.5, MgCl2·6H2O 7, NaH2PO4 1.25,
glucose [C6H12O6] 25, and sucrose [C12H22O11] 75, osmolality = 315 - 320 mOsm) saturated
with 95% O2, 5% CO2. Coronal hypothalamic slices (250 μm) were cut using a vibratome
(VT1200s, Leica Biosystems). Slices containing the PVN were identified based on their
macroscopic features (location posterior to fornix and anterior to hippocampus) and trimmed
and bisected to isolate individual PVN. Then, the trimmed PVN slices were placed into a
slice chamber containing artificial cerebrospinal fluid (aCSF) made of (in mM: NaCl 126,
KCl 2.5, NaHCO3 26, CaCl2·2H2O 2.5, MgCl2·6H2O 1.5, NaH2PO4·H2O 1.25, glucose 10,
osmolality = 295 - 300 mOsm) saturated with 95% O2, 5% CO2. The slice chamber
containing the brain slices was maintained at 35°C in a water bath incubator (Lauda, E100
Ecoline Staredition) for 30 - 40 min. Afterwards, the chamber was removed from the
incubator and held at room temperature (20 - 25°C) for 15 mins before use of the PVN slices.
The chamber was maintained at room temperature for storage of slices until use for the
remainder of the experiment.
Before recording, the slice was transferred to the recording chamber and acclimatized for 15
mins to the temperature and any drugs present in the aCSF (section 2.4). For example, this
acclimatized slices to the presence of the AMPA kainate receptor antagonist, 6,7dinitroquinoxaline-2,3-dione (DNQX; 10 μM, Tocris Bioscience), which was constantly
perfused to isolate GABAA receptors-mediated inhibitory post-synaptic current (IPSC)s.
Throughout recording, the slice was constantly perfused with aCSF saturated with 95% O 2,
5% CO2 at a flow rate of 1-2 mL per min, which was warmed to 30°C using an in-line heater
with a feedback sensor (Scientifica). After being transferred to the recording chamber, the
acute brain slices of PVN were placed under the 40X objective (Scientifica manipulator) of
an infrared differential interference contrast (light) microscope (Scientifica, serial #: 461016).
A DAGE-MTI IR-1000 camera projected the microscope image onto a screen (Insignia).
CRH neurons were identified by their fluorescence under green light (560–520 nm) emitted
from a CoolLED pE-300. Healthy CRH neurons with intact and distinct membranes as was
visualized in phase under the microscope were recorded from using whole-cell patch clamp
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electrophysiology. All equipment including the microscope, recording chamber, and patch
micromanipulators were stabilized using a CleanBench airtable (TMC, Gimbal Piston,
Ametek).

2.3 Electrophysiology
2.3.1 Electrochemical gradients drive potential change across
the membrane
Electrophysiological measures record the current caused by the movement of ions.
Membranes are relatively impermeable to ions. Ions can, however, move through open
channels with their concentration gradient, or may be pumped through active transporters
against their concentration gradient. Current (I) and voltage (V) are related by a factor of
resistance (R) of the material conducting the ions through Ohm’s law:
V = IR
Voltage is the difference in electric potential energy between two positions. Thus, there can
be a potential difference across a cell membrane, which separates ions (electrical potential).
The Nernst equation is used to calculate the potential of an ion across a membrane that
opposes net diffusion of an ion. The magnitude of the Nernst potential is determined by the
ratio of the concentrations of that ion on the in and outside of the membrane; the greater this
ratio the greater the tendency for the ion to diffuse in one direction and therefore the greater
the Nernst potential required to prevent the diffusion. The Nernst equation is:
E=

RT [M]𝑜𝑢𝑡
ln
[M]𝑖𝑛
zF

Where:
E is the membrane potential in volts (V),
T is the temperature in Kelvin (K),
R is the ideal gas constant (8.314459848 JK −1 mol−1 ),
F is Faraday's constant (96485.3328959 Cmol−1 ).
z is the valency (charge) of an ion,
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[M]out is the extracellular concentration of that ion in moles (mol),
[M]in is the intracellular concentration of that ion in moles (mol)
The Nernst equation is derived from the Goldman equation under the assumption that the
membrane is in thermodynamic equilibrium (no net flux of ions). The Goldman equation
accounts for ion permeability, such as by via ion pumps. The Goldman equation is:
+
𝑁
−
∑𝑁
𝑖 (𝑃𝑀𝑖+ ) [𝑀𝑖 ]𝑜𝑢𝑡 + ∑𝑗 (𝑃𝑁𝑗− ) [𝑁𝑗 ]𝑖𝑛
𝑅𝑇
𝐸=
ln (
)
𝑧𝐹
∑𝑁 (𝑃 + ) [𝑀 +] + ∑𝑁 (𝑃 − ) [𝑁 −]
𝑖

𝑀𝑖

𝑖

𝑖𝑛

𝑗

𝑁𝑗

𝑗

𝑜𝑢𝑡

Where:
Pion is the permeability an ion (ms −1 ), thus accounting for flux
The resting membrane potential (Vrest) is the potential of a membrane at rest when it is “at
rest” (not actively undergoing an action potential). The electrochemical gradients made by
ion pumps establishes the Vrest. To calculate the Vrest we use the concentration of these ions
in the intracellular and extracellular space and their permeability; this gives us a Vrest for
neurons of -68 mV primarily contributed to by the leakage of K + out of the cell. The
physiological and experimental concentration of the relevant ions contributing to the Nernst
equilibrium potential are listed Table 2-1.
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Table 2-1: Relevant ion concentrations in the extracellular and intracellular fluids.
Ion concentrations are listed for the physiological and experimental (aCSF and internal)
solutions. Adapted from (Bradbury & Davson, 1965; Contreras, Shoshani, FloresMaldonado, Lázaro, & Cereijido, 1999; Delpire & Staley, 2014; Khazaeipool et al., 2018).
Equilibrium potentials were calculated based on our experimental aCSF and internal
gradients.
Ion
Na+
K+
Cl-

Extracellular (mM)
Physiological
aCSF
130 – 150
153.25
3–9
2.5
100 – 130
136.5

Intracellular (mM)
Physiological
Internal
10
15.4
140
132
4
12

Equilibrium
potential (mV)
+58
-101
-62
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The increased intracellular concentration of Cl- (in mM: physiological = 4, internal = 12)
helps to drive the stronger inward current for recording. Inward and outward current is one
way during voltage clamp to describe the direction of the flow of ions (Yamamoto, Fukami,
& Washio, 1981). Inward ionic current is the flow of cations (positive charge) entering the
cell. In relation to GABA, this is reversed, since GABAA receptors primarily conduct
negative ions (i.e. Cl-). When recording eIPSCs of GABA on CRH neurons, I hold the
membrane potential of the post-synaptic cell at -80 mV, which is below the equilibrium
potential of GABAA receptors (calculated from the ion concentration in our aCSF and
internal), and therefore observe inward ionic current, which is the flow of anions (negative
charge) exiting the cell.

2.3.2 Whole cell patch clamp: pipettes, internal and aCSF
Borsosiliacate glass microelectrode (2-5 MΩ) were pulled using a micropipette puller
(Flaming/Brown, model P1000, Sutter Instrument, CA, USA) and filled with internal
solution consisted of (in mM: K-gluconate 116, KCl 8, Na-gluconate 12, K2-EGTA 1,
HEPES 10, MgCl2 2, K2ATP 4, and Na3GTP 0.3) adjusted for pH (pH = 7.2 - 7.4) and
osmolarity (osmolality = 283 - 289 mOsm).
Once the pipette was in the aCSF under the microscope, the shape and taper were inspected,
and then positive pressure was applied via tubing and maintained by closing a three-way
value; positive pressure helped to clear debris from the pipette’s path when navigating the
slice. A micromanipulator (Scientifica) was used to descend the pipette to target CRH
neurons in the PVN that were identified by the expression of Tdtomato. When positive
pressure was released, the neuron adhered to the electrode and formed a gigaseal (cellattached configuration). To get to whole-cell configuration for recording, the cell membrane
was ruptured with brief suction.
Access resistance (Ra), membrane resistance (Rm) and capacitance of the membrane (Cm)
were examined at least every 5 min during recordings using a Membrane Test function in a
data acquisition software (Clampex 10.7, Molecular devices). The Membrane Test applies a
continuous square wave voltage, then fits an exponential to the responding current to
Q

calculate that Cm = ΔVt , where Qt = Q1 + Q2, the sum of the charge in the transient above the
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steady-state response (Q1) plus the correction factor (Q2) and ΔV is found via the steady-state
equation where ΔI = R

ΔV
a +Rm

(“Membrane Test Algorithms”, 2010). Recordings were

discarded if it exceeded 20 MΩ or changed more than 20% from that of the baseline.
Recordings were terminated if the Rm went below 500 MΩ.
For current-clamp (IC) recordings, the baseline membrane potential of CRH neuron was
adjusted by injecting a constant current of (0- -30pA) to achieve a voltage of approximately 80 mV. CRH neurons were “fingerprinted” to check their type (magnocellular, parvocellular,
pre-autonomic) using an IC protocol of 15 steps lasting 5 seconds each, beginning at -20 pA
and increasing step-wise by 10 pA each time. Recordings were discarded if they were found
to be magnocellular or pre-autonomic. Recordings were discarded if the resting membrane
potential was more depolarized than -42 mV.
For all voltage-clamp experiments, CRH neurons were held at -80 mV. A second
borsosiliacate glass microelectrode (stimulating electrode) was filled with aCSF and placed
ventromedial to the post-synaptic neuron to evoke IPSCs using a simulator (S88 Stimulator;
duration = ~1.1 ms, Volts = 5 - 10 V). Specifically, for all experiments, I evoked a pair of
IPSCs using two stimuli separated by 50 ms (0.2 Hz). The stimulating electrode was moved
until it evoked a strong (minimum = 20 pA, average = 50 pA, and consistently firing) first
evoked IPSC (eIPSC). Once the eIPSC stabilized, I recorded a baseline while flowing normal
aCSF (-5 – 0 min, “baseline”), bath applied the drug for the experiment (0 – 5 min, “drug”),
and then washed the drug out with aCSF (5 – 15 min, “post-drug”).

2.4 Drugs
This study used various agonists and antagonists for EP receptors. The names of all the drugs
used is listed with their function in Table 2-2. All drugs were obtained from Cayman
Chemical (Michigan, USA). The drugs were prepared into aliquots using the solvent listed in
Table 2-2. Aliquots were stored at -20°C until the day of the experiment. As required for the
experiments, aliquots of the drugs were diluted to the appropriate concentration (Table 2-2)
in aCSF. The maximum concentration of the solvents (ethanol or dimethylsulfoxide
[DMSO]) was 0.2% in the final working solution. The final concentration of each drug used
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was chosen based on its dose-response curves or use ex vivo, or if unavailable based on its
published pharmacological values.
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Table 2-2: Drug information.
The name, function, and catalogue number of all used drugs are listed. The binding
efficiency of the drug is described by the dissociation constant (Ki), which is like the affinity
constant of the enzyme and inhibitor complex, half maximal inhibitory concentration (IC50),
the concentration that reduces operation of the target by 50%, or half maximal effective
concentration (EC50), the concentration that increases operation of the target by 50%. The
Cheng-Prussoff equation allows conversion of IC50 values to a more universal Ki for direct
comparison of data, where K i =

IC50
[S]
)
Km

(1+

if [S] is the substrate concentration and Km is

Michaelis constant. The binding value and ex vivo literature were used to select the
concentration of drug used in this thesis. Drugs were aliquoted in solvent to a concentration
under saturation level. Aliquots were diluted in aCSF to the final concentration.
Function

Drug name

Cat #

EP1-4
agonist

PGE2

14010

EP1
agonist
EP2
agonist

Iloprost

18215

CP 544,326

22945

EP3
agonist
EP4
agonist

Sulprostone

14765

L-902,688

10007712

EP1
antagonist

GW
848687X

10010410

EP2
antagonist

PF04418948

15016

EP3
antagonist

L-798,106

11129

EP4
antagonist

BCG 201531(HCl)

19742

Binding value

Ki = 1-10 nM depending on
receptor (Coleman, Smith, &
Narumiya, 1994)
Ki = 11 nM (Abramovitz et al.,
2000)
IC50 = 15 nM for rat EP2, IC50s =
>3,200 nM for EP1, EP2,
EP4 (Prasanna et al., 2011)
Ki = 0.35 nM, IC50 = 0.01 µM
(Negishi et al., 1994)
Ki = 0.38 nM, EC50 = 0.6 nM for
EP4, >4,000-fold selective over
EP1, EP2, EP3 (Young et al.,
2004)
IC50 = 2.5 nM for EP1, >400-fold
selective over EP1, EP2,
EP4 (Giblin et al., 2007)
IC50 = 16 nM for EP2 , >1000fold selective over EP1, EP3,
EP4 (af Forselles et al., 2011)
Ki = 0.3, 916, 5,000, >5,000 nM
for EP3, EP4, EP1, EP2,
respectively (Juteau et al., 2001)
Ki = 11.7, >10,000, >10,000 nM
for EP4, EP2, EP3, respectively
(Maubach et al., 2009)

Final
concentration (µM)
1

1
1

1
0.1

Aliquot
solvent,
saturation
Ethanol,
>100
mg/mL
Ethanol, 25
mg/mL
DMSO,
30 mg/mL
Ethanol,
25 mg/mL
Ethanol,
30 mg/mL

1

Ethanol,
5 mg/mL

1

DMSO,
16 mg/mL

1

DMSO,
10 mg/mL

1

DMSO,
1 mg/mL

37

2.5 Data processing and analysis
All the electrophysiological patch clamp recordings were amplified using Multiclamp 700B
(Axon CNS Molecular devices), low-pass filtered between 1-10 kHz, and digitized at 20 kHz
using a Digidata 1550B (Axon Instruments Molecular devices Electrophysiology). The
recordings were analyzed off-line using Clampfit 10.7 software (pClamp, Molecular
devices). eIPSC amplitude was calculated by subtraction of each traces’ peak amplitude from
the 1 second long pre-stimulation baseline. All data was normalized and presented as a
percentage of the average baseline (-5 - 0 min, pre-drug application) in the 1-minute bins
represented as a time-course plot. The effects were observed in the post-drug bin (5 - 10 min)
after drug application reached maximum concentration and had time to act. The frequency
and amplitude of eIPSCs, the paired-pulse ratio, and the coefficient of variation (CV) were
analyzed and are presented in 1-minute bins. sIPSC events were detected, confirmed visually,
and counted for frequency, with amplitude calculated similar to eIPSCs using MiniAnalysis
software (Synaptosoft). Data are presented as many individual recordings or mean ± s.e.m.

2.6 Statistical analysis
All statistical analyses were performed in GraphPad Prism 7 (GraphPad Software Inc., CA,
USA). Statistical significance was tested using one-way sample t-test in all experiments with
normalized data; t-tests contrasted the post-drug bin (5 - 10 min) with the hypothetical mean
of 100%. In cases while comparing absolute values, a paired parametric t-test was used to
compare the wash time bin (5 - 10 min) with the baseline bin (-5 - 0 min). To analyze the
correlation between two variables, linear regression analysis was applied. An R 2 coefficient
was calculated as a measure of fit and a t-test was performed comparing the slope of the
regression line to 0. A probability value (p) of < 0.05 was considered as statistically
significant.

2.7 Synaptic properties assessed: Identifying pre- and postsynaptic locus of effect
The efficacy of synaptic transmission is generally determined by the following three
independent variables: the probability of the neurotransmitter release (P r), numbers of
synapses (N), or quantal size (Q). Pr and N typically reflects pre-synaptic mechanisms of
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neurotransmitter release, whereas Q reflects the post-synaptic receptor function. Plastic
changes of a synapse could affect any combinations of Pr, N and Q. During patch clamp
electrophysiology, one can record the post-synaptic current (PSC) or voltage. While
recording PSC, it is possible to use specific protocols to record synaptic properties that can
be used to determine Pr, N and Q associated with synaptic plasticity as is summarized in
Table 2-3 (Branco & Staras, 2009; Faber & Korn, 1991; Korn & Faber, 1991). These
synaptic properties include: the paired-pulse ratio (PPR) and the CV of the eIPSCs as well as
the frequency and amplitude of the sIPSCs.

2.7.1 Paired-pulse ratio
When recording eIPSCs, two pulses are delivered with an interstimulus interval of 50 ms,
which evoked 2 separate eIPSCs. The PPR is the amplitude of the second eIPSC over the
P

first eIPSC (PPR = P2 ). Synapses with high Pr tend to have PPR < 1, while low Pr synapses
1

tend to have PPR > 1. If a type of plasticity alters the PPR, it indicates changes in P r and presynaptic locus of the plasticity mechanism. Paired-pulse depression (decreased PPR)
generally indicate an increase in Pr, as high Pr uses up readily releasable vesicles during the
first pulse so fewer vesicles are available for the second pulse. Conversely, paired-pulse
facilitation (increased PPR) generally indicates a decrease in Pr, due to the combinations of
less depletion of readily releasable vesicles by the first pulse and accumulation of Ca2+ in the
pre-synaptic terminals by two consecutive pulses. When synaptic plasticity is due to the
changes in the post-synaptic receptor functions, the amplitude of the first and second peaks
should be affected equally, and thus PPR should remain stable. Importantly, a lack of change
of PPR is not an indication of a post-synaptic mechanism, but rather a lack of indication of a
pre-synaptic mechanism. Some post-synaptic mechanisms may affect PPR such as
desensitization of post-synaptic receptors, but these have not been well studied (Blitz, Foster,
& Regehr, 2004). Generally, PPR a measure fairly specific for pre-synaptic mechanisms
(Fioravante & Regehr, 2011).
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2.7.2 Coefficient of Variation
1

The CV2 is a measure related to the variability of the eIPSCs, where the CV is calculated as:
CV =

σ
μ

Where:
σ is the standard deviation,
μ is the mean
Each eIPSC is composed of a sum of many different contributions of individual vesicle
1

releases and synapse firing. A variable synapse has high CV and thus low CV2. One major
contributor to stable (low CV) synapses is a large number of active pre-synaptic release sites
(high N), as the average firing of a larger population is more consistent. By contrast, more
variable synapses have fewer contributing partners making failure of firing/vesicles release
1

evident. CV2 is a characteristic of the Pr and the N of the pre-synaptic neuron. If a treatment
1

affects the pre-synaptic site of a synapse, altering its Pr or N, then the CV2 should change
1

(facilitation or depression). If CV2 decreases, then the synapse is more variable, potentially
1

due to fewer functional pre-synaptic release sites (decreased N). Or, if CV2 decreases, it may
be due to a decrease of Pr. By contrast, the post-synaptic receptor population do not create
1

variability; if the treatment causes an effect via post-synaptic receptors, then the CV2 remains
unchanged.

2.7.3 sIPSC Frequency
The frequency of the sIPSC generally indicates the frequency of neurotransmitter release
from the pre-synaptic terminals and is therefore determined by the combination of Pr and N.
In addition, sIPSC frequency is influenced by the frequency of (spontaneous) action potential
firing of the pre-synaptic neurons. Thus, changes in sIPSC frequency informs changes in Pr,
N and/or pre-synaptic neurons’ action potential firing. Fewer synaptic partners (low N) or
fewer readily releasable vesicles (low Pr) decreases the change of spontaneous vesicle fusion
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(frequency). By contrast, if the treatment causes an effect via post-synaptic receptors, then
the sIPSC frequency remains unchanged.

2.7.4 sIPSC Amplitude
The average amplitude of sIPSCs is a characteristic of the Q, a major predictor of postsynaptic neuron receptor modulation. Q refers to the population average of the post-synaptic
response to the release of a single vesicle that contains neurotransmitter. Thus, in general, Q
is modulated post-synaptically by changing the response to the released transmitter. sIPSC
amplitude decreases may reflect a decrease in the responsiveness of the post-synaptic
receptors to a vesicle release (decreased Q). By contrast, if the treatment causes an effect via
pre-synaptic receptors, then the sIPSC amplitude remains unchanged. However, while Q is
generally considered post-synaptic, some evidence towards pre-synaptic affects includes
changes in the amount of neurotransmitter packaged, given that post-synaptic receptors are
not saturated (Edwards, 2007).
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Table 2-3: Changes of synaptic properties that are associated with synaptic plasticity
changes.
Decreases in the probability of release (Pr), numbers of synapses (N), and quantal size (Q)
are associated with changes in the paired pulse ratio (PPR), coefficient of variation (CV),
spontaneous inhibitory post-synaptic current (sIPSC) amplitude and sIPSC frequency. P r and
n are associated with pre-synaptic loci of effects, while Q is associated with post-synaptic a
locus of effect.
Synaptic
locus
PrePrePost-

Synaptic plasticity
mechanism
↓ Pr
↓n
↓q

PPR
↑
-

1
CV2
↓
↓
-

sIPSC
Amp.
↓

sIPSC Freq.
↓
↓
-
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Chapter 3
3 Results
3.1 PGE2 depresses GABAergic synaptic transmission onto
CRH neurons via a pre-synaptic mechanism
Using rats, our former M.Sc. student recently showed that PGE2 suppresses GABAergic
synaptic transmission onto PNCs in the PVN, a plausible mechanism for immune-induced
activation of the HPA axis (Khazaeipool et al., 2018). My thesis is built on this finding –
aiming to further examine the effects of prior psychological stress on this PGE 2-induced
GABA synapse plasticity. To this end, I first aimed to change our animal model from rat to
mouse because of the availability of a CRH reporter mouse line (Cusulin et al., 2013). In rats,
PNCs are identified based on their morphology and electrophysiological fingerprint (Figure
1-5). While PNCs are operationally defined as putative CRH neurons, they also include nonCRH neurons like TRH-, and GHIH-expressing neurons (Ceccatelli et al., 1989; Pammer et
al., 1988; Stern, 2015). The transition to a mouse model was essential to accurately identify
CRH neurons and reduce variability in the data due to the cellular heterogeneity. Therefore,
the first aim of my thesis is to replicate the finding of the mechanism of PGE 2 action from the
rat model in the CRH reporter mouse model where CRH neurons can be visually identified in
slice electrophysiology by the expression of TdTomato (Cusulin et al., 2013).
Consistent with our rat study (Khazaeipool et al., 2018), we found that bath application of
PGE2 (1 µM for 5 min) decreased the amplitude of eIPSCs (53.25 ± 11.01% of the baseline,
p = 0.0022, n = 10) (Figure 3-1 A, B, C) recorded in CRH neurons in PVN slices prepared
from naïve mice. Our rat study also reported that PGE2 achieves this depression of
GABAergic transmission via a pre-synaptic mechanism as was evidenced by 1) an increase
1

in the PPR, 2) decrease in the CV2, 3) a decrease in the sIPSC frequency, and 4) no change in
the sIPSC amplitude, according to Table 2-3. Consistent with this, the PGE2-induced
depression of eIPSC amplitude in mice was accompanied by an increase in PPR (138.10 ±
1

9.62% of baseline, p = 0.0033, n = 10) and a decrease in CV2 (32.04 ± 8.53% of baseline, p <
0.0001, n = 10) (Figure 3-1 C, D). The change in eIPSC amplitude had tendencies to
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1

correlate with the change in PPR (R2 = 0.3866, p = 0.0549) and CV2 (R2 = 0.1575, p = 0.2562)
(Figure 3-1 D). Similar to our rat study, the analysis of sIPSCs revealed that PGE 2 decreased
the frequency of sIPSCs (61.41 ± 11.33% of baseline, p = 0.0078, n = 10) (Figure 3-1 E, G,
H, I) but did not change the mean amplitude of the sIPSCs (96.58 ± 3.07% of baseline, p =
0.2938, n = 10) (Figure 3-1 E, F, H, I). These changes in synaptic properties are consistent
with the pre-synaptic mechanisms suggested in previous studies (Khazaeipool et al., 2018).
Together, these data suggest that PGE 2 depress GABAergic transmission onto PVN-CRH
neurons in mice via a pre-synaptic mechanism, similar to what we have reported in PNCs in
rats (Khazaeipool et al., 2018).
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Figure 3-1: PGE2 depressed GABA transmission on CRH neurons in naïve mice.
8

(A) An example of a typical eIPSC recording in a naïve mouse, comparing baseline (black)
and after PGE2 (blue) application. (B) Individual time-course of eIPSC 1 amplitude. (C)
1

Summary time-course of normalized eIPSC 1 amplitude, PPR, and CV2. (D) Correlation plot
1

of eIPSC (% baseline) with PPR (orange) or CV2 (purple) after treatment with PGE2. The
1

lines represent the linear best fit regression for PPR (orange) and CV2 (purple). (E) An
example of a typical sIPSC recording in a naïve mouse, comparing baseline (black) and after
PGE2 (blue) application. (F) Individual time-course of sIPSC frequency and (G) sIPSC
amplitude. (H) Summary time-course of normalized sIPSC frequency (orange) and amplitude
(purple). (I) Correlation plot of eIPSC (% baseline) with sIPSC frequency (orange) or
amplitude (purple) after treatment with PGE2. The lines represent the linear best fit
regression for sIPSC frequency (orange) or amplitude (purple). For all graphs, the horizontal
line represents the time and duration of drug application. Data are mean ± s.e.m.
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3.2 Acute restraint stress alters the PGE2 depression of
GABAergic synaptic transmission onto CRH neurons
Psychological stress alters the sensitivity of the HPA axis to inflammation in vivo (Johnson et
al., 2002; Gadek-Michalska et al., 2005). My thesis asked whether prior exposure to
psychological stress alters the actions of PGE 2 on the GABAergic synapses onto PVN-CRH
neurons. To test this, we challenged a mouse with a one hour restraint stress, a widely used
psychological stress in rodents (Chu et al., 2016; Gadek-Michalska et al., 2005; Roper,
Craighead, O’Carroll, & Lolait, 2010; Zimprich et al., 2014) and immediately after the end of
restraint prepared acute brain slices for electrophysiological recordings. We found that
restraint stress made the effects of PGE 2 heterogeneous. That is, in brain slices from acutely
stress mice, PGE2 depressed some GABA transmission on CRH neurons (42.90 ± 6.21% of
baseline, p < 0.0001, n = 9 of 13) (Figure 3-2 A [i], B, C) but also potentiated GABA
signaling other neurons (135.67 ± 12.60% of baseline, p = 0.0472, n = 4 of 13) (Figure 3-2 A
[ii], B, C). The magnitude of depression after stress was similar to that of naïve animal PGE 2
application (42.90 ± 6.21% of baseline vs. 53.25 ± 11.01% of the baseline, p = 0.4388).
1

I next analyzed changes in the PPR, CV2, sIPSC frequency and amplitude to tease out the preand/or post-synaptic mechanisms of the synaptic changes. Since post-stress PGE2 caused two
different responses – depression and potentiation – of the eIPSC, I assessed the synaptic
properties of these recordings separately. Like in naïve conditions, the depression of eIPSC
amplitude was accompanied by an increase in PPR (130.10 ± 9.47% of baseline, p = 0.0130,
1

n = 9) and a decrease in CV2 (34.35 ± 10.18% of baseline, p = 0.0002, n = 9) (Figure 3-2 C,
D). Likewise, there was a trend of decrease in sIPSC frequency that did not reach statistical
significance (61.33 ± 18.06% of the baseline, p = 0.0695, n = 8 [1 recording excluded:
insufficient baseline sIPSC frequency (<0.5 Hz)]) (Figure 3-2 E [i], G, H, I), whereas there
was no change in sIPSC amplitude (91.28 ± 4.25% of the baseline, p = 0.0792, n = 8)
(Figure 3-2 E [i], F, H, I). These data suggest that PGE2-induced eIPSC depression in
acutely stressed animals is likely pre-synaptic, like in naïve conditions. When PGE2
potentiated the amplitude of eIPSCs, this potentiation was accompanied by a decrease in the
1

PPR (89.34 ± 1.40% of baseline, p = 0.0047, n = 4) and a trend toward an increase in the CV2
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(179.80 ± 27.19% of baseline, p = 0.0607, n = 4) (Figure 3-2 E [ii], G, H, I). Neither the
frequency (93.47 ± 39.15% of the baseline, p = 0.8782, n = 4) nor the mean amplitude
(103.90 ± 8.86% of the baseline, p = 0.7043, n = 4) (Figure 3-2 E [ii], F, H, I) of sIPSCs
changed. Together, these data suggest that PGE2 potentiates eIPSC amplitude via an increase
in the number of functional synapses with little changes in Pr and Q.
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Figure 3-2: Acute restraint stress alters PGE2-induced effects on GABA transmission
9

on CRH neurons.
(A) An example of a typical eIPSC recording in an acutely restrained mouse, comparing
baseline (black) and after PGE2 (red) application for a neuron that (i) depressed and (ii)
potentiated. (B) Individual time-course of eIPSC 1 amplitude. (C) Summary time-course of
1

normalized eIPSC 1 amplitude, PPR, and CV2 for the population of neurons that depressed
(dark) and potentiated (light). (D) Correlation plot of eIPSC (% baseline) with PPR (orange)
1

or CV2 (purple) after treatment with PGE2. The lines represent the linear best fit regression for
1

PPR (orange) and CV2 (purple) for the population of neurons that depressed (dark) and
potentiated (light). (E) An example of a typical sIPSC recording in an acutely restrained
mouse, comparing baseline (black) and after PGE 2 (red) application for a neuron that (i)
depressed and (ii) potentiated. (F) Individual time-course of sIPSC frequency and (g) sIPSC
amplitude. (H) Summary time-course of normalized sIPSC frequency (orange) and amplitude
(purple) for the population of neurons that depressed (dark) and potentiated (light). (I)
Correlation plot of eIPSC (% baseline) with sIPSC frequency (orange) or amplitude (purple)
after treatment with PGE2. The lines represent the linear best fit regression for sIPSC
frequency (orange) or amplitude (purple) for the population of neurons that depressed (dark)
and potentiated (light). For all graphs, the horizontal line represents the time and duration of
drug application. Data are mean ± s.e.m.
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3.3 Depression of GABAergic synaptic transmission onto CRH
neurons is mediated by EP3
Our data thus far demonstrated that prior exposure to a single restraint stress alters the effects
of PGE2 on GABA synapses. Specifically, after restraint stress PGE2 potentiated some
synapses/cells. Our previous rat study showed that the PGE2-mediated depression of GABA
release is mediated by EP3 receptor subtype (Khazaeipool et al., 2018). These data lead us to
hypothesize that restraint stress down-regulated EP3 receptor in some, but not, all synapses
and that this down-regulation unmasked an opposing potentiation.
In slices from naïve mice, bath application of EP3 agonist (sulprostone, 1 µM for 5 min)
reduced the eIPSCs amplitude (55.81 ± 5.80% of baseline, p < 0.0001, n = 9) (Figure 3-3 A,
B, C), which is similar in magnitude to that of PGE2 (vs. 53.25 ± 11.01% of the baseline, p =
0.8568). This is again in line with our recent finding in rats regarding the roles of EP3
receptors mediating PGE2-mediated depression of eIPSCs (Khazaeipool et al., 2018). The
1

analysis of synaptic parameters found that EP3 agonist decreased CV2 (47.58 ± 10.22% of
baseline, p = 0.0009, n = 9). However, it did not change PPR (108.90 ± 8.56% of baseline, p
= 0.3314, n = 9) (Figure 3-3 C, D). The lack of PPR change by EP3 agonist, by contrast to its
robust increase by PGE2 (108.90 ± 8.56% of baseline, vs. 138.10 ± 9.62% of baseline, p =
0.0382) suggests that it is the contribution of other EP receptors (EP1, EP2, and EP4) that
increases PPR after the application of PGE2. EP3 agonist decreased the frequency (46.60 ±
8.41% of baseline, p = 0.0002, n = 9) (Figure 3-3 E, G, H, I) without changing the mean
amplitude (99.20 ± 9.94% of baseline, p = 0.9382, n = 9) of sIPSCs (Figure 3-3 E, F, H, I).
Overall, the EP3-mediated depression of eIPSCs is accompanied by changes indicative of a
decrease in the number of functional GABA synapses, which is consistent with pre-synaptic
synaptic depression mechanism. The decrease in cAMP due to Gαi/o has previously been
linked to decreasing neurotransmitter release (Atwood, Lovinger, & Mathur, 2014),
consistent with the proposed pre-synaptic mechanism.
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Figure 3-3: EP3 decreases the amplitude of eIPSCs in naïve mice.
(A) An example of a typical eIPSC recording in a naïve mouse, comparing baseline (black)
and after EP3 agonist (blue) application. (B) Individual time-course of eIPSC 1 amplitude.
1

(C) Summary time-course of normalized eIPSC 1 amplitude, PPR, and CV2. (D) Correlation
1

plot of eIPSC (% baseline) with PPR (orange) or CV2 (purple) after treatment with EP3
1

agonist. The lines represent the linear best fit regression for PPR (orange) and CV2 (purple).
(E) An example of a typical sIPSC recording in a naïve mouse, comparing baseline (black)
and after EP3 agonist (blue) application. (F) Individual time-course of sIPSC frequency and
(G) sIPSC amplitude. (H) Summary time-course of normalized sIPSC frequency (orange)
and amplitude (purple). (I) Correlation plot of eIPSC (% baseline) with sIPSC frequency
(orange) or amplitude (purple) after treatment with EP3 agonist. The lines represent the linear
best fit regression for sIPSC frequency (orange) or amplitude (purple). For all graphs, the
horizontal line represents the time and duration of drug application. Data are mean ± s.e.m.
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3.4 Acute restraint stress does not alter the EP3-mediated
depression of GABAergic synaptic transmission onto CRH
neurons
We next examined the effects of applying an EP3 agonist on slices from restraint stressed
mice. Contrary to our hypothesis that restraint stress impairs the EP3 receptor-mediated
GABA synapse depression, EP3 agonist decreased the amplitude of the eIPSCs in slices from
restraint stressed mice (45.02 ± 6.99% of baseline, p = 0.0001, n = 8) (Figure 3-4 A, B, C) in
the magnitude comparable to what we found in naïve slices EP3 application (45.02 ± 6.99%
of baseline vs. 55.81 ± 5.80% of baseline, p = 0.2585). These data indicate that EP3-mediated
depression is intact after acute stress. Similar to naïve mice, EP 3 agonist applied to the
1

acutely stressed mice slices decreased the CV2 (43.81 ± 11.81% of baseline, p = 0.0021, n =
8). EP3 application to stressed mice increased PPR (131.80 ± 13.03% of baseline, p = 0.0450,
n = 8) (Figure 3-4 C, D), unlike in naïve slices (vs. 108.90 ± 8.56% of baseline, p = 0.0542),
pointing to a possibility that stress can contribute to the increase in PPR. sIPSC analysis
showed that EP3 agonist decreased frequency (64.23 ± 14.19% of baseline, p = 0.0398, n = 8)
(Figure 3-4 E, G, H, I) but did not change amplitude (91.54 ± 6.40% of baseline, p = 0.2276,
n = 8) (Figure 3-4 E, F, H, I). Overall, these data suggest that EP3 receptor continues, after
restraint stress, to have a pre-synaptic locus and depress GABA transmission.
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Figure 3-4: Acute stress does not modulate EP3-mediated suppression of GABA release.
10

(A) An example of a typical eIPSC recording in an acutely restrained mouse, comparing
baseline (black) and after EP3 agonist (red) application. (B) Individual time-course of eIPSC
1

1 amplitude. (C) Summary time-course of normalized eIPSC 1 amplitude, PPR, and CV2. (D)
1

Correlation plot of eIPSC (% baseline) with PPR (orange) or CV2 (purple) after treatment with
1

EP3 agonist. The lines represent the linear best fit regression for PPR (orange) and CV2
(purple). (E) An example of a typical sIPSC recording in an acutely restrained mouse,
comparing baseline (black) and after EP3 agonist (red) application. (F) Individual time-course
of sIPSC frequency and (G) sIPSC amplitude. (H) Summary time-course of normalized
sIPSC frequency (orange) and amplitude (purple). (I) Correlation plot of eIPSC (% baseline)
with sIPSC frequency (orange) or amplitude (purple) after treatment with EP3 agonist. The
lines represent the linear best fit regression for sIPSC frequency (orange) or amplitude
(purple). For all graphs, the horizontal line represents the time and duration of drug
application. Data are mean ± s.e.m.
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3.5 Blocking EP3 receptor removes the PGE2 suppression of
GABA release onto CRH neurons in naïve mice
Our next hypothesis was that restraint stress altered non-EP3 receptors that cause an opposing
potentiation and overcome the EP3-mediated depression of GABA release. To test this, we
applied PGE2 in the presence of an EP3 antagonist. In slices from naïve mice, PGE2 in the
presence of EP3 antagonist (L-798, 106, 1 µM for recording duration) did not depress the
eIPSC amplitude but rather resulted in a trend toward potentiation that did not reach
statistical significance (112.50 ± 5.77% of baseline, p = 0.0590, n = 10) (Figure 3-5 A, B,
C). EP3 antagonist fully blocks PGE2-induced depression of GABA (112.50 ± 5.77% of
baseline vs. 53.25 ± 11.01% of the baseline, p = 0.0002). Consistent with the block of PGE 2
1

effects, there was no change in PPR (92.82 ± 3.86% of baseline, p = 0.0958, n = 10), CV2
(109.20 ± 19.63% of baseline, p = 0.6515, n = 10) (Figure 3-5 C, D), sIPSC frequency
(90.30 ± 26.15% of baseline, p = 0.7233, n = 7 [remainder of data still in analysis])) (Figure
3-5 E, G, H, I) or sIPSC amplitude (112.90 ± 7.99% of baseline, p = 0.1567, n = 7
[remainder of data still in analysis]) (Figure 3-5 E, F, H, I). These data further support that
PGE2 depresses GABA synapses via EP3 receptors in slices from naïve mice.

57

58
Figure 3-5: EP3 antagonist blocks suppression of eIPSCs in naïve mice.
11

(A) An example of a typical eIPSC recording in a naïve mouse, comparing baseline EP3
antagonist (black) and after PGE2 agonist (blue) application. (B) Individual time-course of
eIPSC 1 amplitude. (C) Summary time-course of normalized eIPSC 1 amplitude, PPR, and
1
CV2

1

. (D) Correlation plot of eIPSC (% baseline) with PPR (orange) or CV2 (purple) after

treatment with PGE2 during EP3 antagonist. The lines represent the linear best fit regression
1

for PPR (orange) and CV2 (purple). (E) An example of a typical sIPSC recording in a naïve
mouse, comparing baseline EP3 antagonist (black) and after PGE2 agonist (blue) application.
(F) Individual time-course of sIPSC frequency and (G) sIPSC amplitude. (H) Summary timecourse of normalized sIPSC frequency (orange) and amplitude (purple). (I) Correlation plot
of eIPSC (% baseline) with sIPSC frequency (orange) or amplitude (purple) after treatment
with PGE2 during EP3 antagonist. The lines represent the linear best fit regression for sIPSC
frequency (orange) or amplitude (purple). For all graphs, the horizontal line represents the
time and duration of drug application. Data are mean ± s.e.m.
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3.6 Acute restraint stress alters the non-EP3-mediated
depression of GABAergic synaptic transmission onto CRH
neurons
We next repeated the experiment in slices from restraint stressed mice. We found that the
presence of EP3 antagonist unmasked PGE2-mediated potentiation after restraint stress
(114.50 ± 4.08% of baseline, p = 0.0075, n = 9) (Figure 3-6 A, B, C). However, the
magnitude of the potentiation was not significantly larger than naïve (114.50 ± 4.08% of
baseline vs. 112.50 ± 5.77% of baseline, p = 0.7843). PGE2 in the presence of EP3 antagonist
decreased PPR (88.97 ± 4.37% of baseline, p = 0.0355, n = 9) (Figure 3-6 C, D). This
suggests that the potentiation of eIPSC amplitude involves an increase in P r and thus a pre1

synaptic mechanism. On the other hand, we did not observe significant change in change CV2
(116.40 ± 23.55% of baseline, p = 0.5054, n = 9) (Figure 3-6 C, D) or sIPSC frequency
(94.49 ± 14.33% of baseline, p = 0.7107, n = 9) (Figure 3-6 E, G, H, I). There was an
increase of the sIPSC amplitude (115.80 ± 6.24% of baseline, p = 0.0355, n = 9) (Figure 3-6
E, F, H, I), pointing to a possibility for post-synaptic mechanisms that is recruited by nonEP3 receptor signaling only after restraint stress.
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Figure 3-6: Acute stress may modulate non-EP3-mediated suppression of GABA
12

release.
(A) An example of a typical eIPSC recording in an acutely restrained mouse, comparing
baseline EP3 antagonist (black) and after PGE2 agonist (red) application. (B) Individual timecourse of eIPSC 1 amplitude. (C) Summary time-course of normalized eIPSC 1 amplitude,
1

1

PPR, and CV2. (D) Correlation plot of eIPSC (% baseline) with PPR (orange) or CV2 (purple)
after treatment with PGE2 during EP3 antagonist. The lines represent the linear best fit
1

regression for PPR (orange) and CV2 (purple). (E) An example of a typical sIPSC recording in
an acutely restrained mouse, comparing baseline EP3 antagonist (black) and after PGE2
agonist (red) application. (F) Individual time-course of sIPSC frequency and (G) sIPSC
amplitude. (H) Summary time-course of normalized sIPSC frequency (orange) and amplitude
(purple). (I) Correlation plot of eIPSC (% baseline) with sIPSC frequency (orange) or
amplitude (purple) after treatment with PGE2 during EP3 antagonist. The lines represent the
linear best fit regression for sIPSC frequency (orange) or amplitude (purple). For all graphs,
the horizontal line represents the time and duration of drug application. Data are mean ±
s.e.m.
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3.7 EP2 and EP4 receptors potentiate GABA synapses onto
PVN-CRH neurons but are not upregulated by stress
We next sought for the mechanisms through which PGE 2 potentiated GABA synapses. We
hypothesized that EP2 and EP4 receptors were likely to mediate the potentiation as they are
coupled to Gαs protein: Gαs signaling via cAMP signaling has been shown to stimulate
neurotransmitter release from pre-synaptic terminals (Atwood, Lovinger, & Mathur, 2014).
We predicted EP2 and/or EP4 receptor activation potentiates GABAergic synaptic
transmission onto PVN-CRH neurons and that restraint stress augments this potentiation to
overcome EP3-mediated depression in some synapses.
Co-application of EP2 agonist (CP 544,326, 1 µM for 5 min) and EP4 agonist (L-902,688, 0.1
µM for 5 min) significantly increased eIPSC amplitude (165.60 ± 17.35% of baseline, p =
0.0194, n = 5) in naïve mice (Figure 3-7 A, B, C). EP2 and EP4 agonist application together
did not change PPR (106.00 ± 6.78% of baseline, p = 0.4241, n = 5), yet there was a trend to
1

increase the CV2 (261.30 ± 69.35% of baseline, p = 0.0806, n = 5) (Figure 3-5 C, D). Our
data suggest that EP2 and EP4 mediate potentiation in naïve conditions. Based on the changes
1

in CV2, the synaptic locus of the potentiation is likely to involve an increase in the number of
synapses.
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Figure 3-7: EP2 and EP4 together mediate potentiation in naïve mice.
13

(A) An example of a typical eIPSC recording in a naïve mouse, comparing baseline (black)
and after EP2 and EP4 agonist (blue) application. (B) Individual time-course of eIPSC 1
1

amplitude. (C) Summary time-course of normalized eIPSC 1 amplitude, PPR, and CV2. (D)
1

Correlation plot of eIPSC (% baseline) with PPR (orange) or CV2 (purple) after treatment with
EP2 and EP4 agonist. The lines represent the linear best fit regression for PPR (orange) and
1
CV2

(purple). For all graphs, the horizontal line represents the time and duration of drug
application. Data are mean ± s.e.m.
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We next asked if an acute restraint stress could enhance this potentiation mechanism, which
aimed to explain the increased potentiation after PGE2. To this end, we repeated the
experiment in slices from restraint stressed mice. Application of EP2 receptor agonist with
EP4 agonist increased eIPSC amplitudes (136.70 ± 7.17% of baseline, p = 0.0037, n = 6)
(Figure 3-8 A, B, C). However, contrary to my prediction, EP2 and EP4 receptor-mediated
potentiation is not greater after stress than in naïve conditions (136.70 ± 7.17% of baseline
vs. 165.60 ± 17.35% of baseline, p = 0.1330). During the potentiation of eIPSC amplitude,
there was no change in PPR (93.00 ± 3.52% of baseline, p = 0.1033, n = 6) and a trend to
1

increase CV2 (153.6 ± 26.34% of baseline, p = 0.0973, n = 6) (Figure 3-8 C, D). Overall, this
data suggests that EP2 and EP4 mediate a potentiation that remains intact after stress with no
indication of upregulation of EP2 and EP4.
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Figure 3-8: EP2 and EP4 together do not mediate greater potentiation after acute
14

restraint stress.
(A) An example of a typical eIPSC recording in an acutely restrained mouse, comparing
baseline (black) and after EP2 and EP4 agonist (red) application. (B) Individual time-course
of eIPSC 1 amplitude. (C) Summary time-course of normalized eIPSC 1 amplitude, PPR, and
1
CV2

. (D) Correlation plot of eIPSC (% baseline) with PPR (orange) or

1
CV2

(purple) after

treatment with EP2 and EP4 agonist. The lines represent the linear best fit regression for PPR
1

(orange) and CV2 (purple). For all graphs, the horizontal line represents the time and duration
of drug application. Data are mean ± s.e.m.
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3.8 Blocking either EP2 or EP4 receptor abolishes PGE2mediated potentiation
To further investigate the roles of EP2 and EP4 in GABA synapse transmission, we applied
PGE2 in the presence of the antagonist for either EP2 or EP4 receptor. Because we observed
PGE2-mediated potentiation only after restraint stress, these experiments were done in slices
in restraint stressed mice. In the presence of EP2 receptor antagonist (PF-04418948, 1 µM for
recording duration), PGE2 application potently depressed eIPSC amplitudes in all synapses
(29.09 ± 4.21% of baseline, p < 0.0001, n = 6) (Figure 3-9 A, B, C), indicating that the
PGE2-mediated potentiation requires EP2 receptor signaling. The depression of eIPSCs by
PGE2 in the presence of EP2 receptor antagonist was accompanied by an increase in PPR
1

(159.60 ± 14.77% of baseline, p = 0.0100, n = 6) and a decrease in CV2 (14.42 ± 2.69% of
baseline, p < 0.0001, n = 6) (Figure 3-9 C, D).
Likewise, EP4 receptor antagonist (BCG-20-1531(HCl), 1 µM for recording duration)
abolished PGE2-mediated potentiation, resulting in a homogeneous depression (33.89 ±
7.00% of baseline, p = 0.0007, n = 5) (Figure 3-10 A, B, C). EP4 antagonist during PGE2
application did not change the PPR (127.70 ± 20.46% of baseline, p = 0.2477, n = 5), but
1

significantly decreased the CV2 (29.11 ± 8.91% of baseline, p = 0.0013, n = 5) (Figure 3-10
C, D). These data are in line with our earlier finding that EP3 receptor activation depressed
eIPSC amplitude via the inhibition of GABA release from the pre-synaptic terminals.
Additionally, that all potentiation is blocked by antagonizing just one of the EP2 and EP4
receptors suggests that both are necessary for potentiation.
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Figure 3-9: Blocking EP2 receptor abolishes potentiation after acute restraint stress.
15

(A) An example of a typical eIPSC recording in an acutely restrained mouse, comparing
baseline EP2 antagonist (black) and after PGE2 agonist (red) application. (B) Individual timecourse of eIPSC 1 amplitude. (C) Summary time-course of normalized eIPSC 1 amplitude,
PPR, and

1
CV2

. (D) Correlation plot of eIPSC (% baseline) with PPR (orange) or

1
CV2

(purple)

after treatment with PGE2 during EP2 antagonist. The lines represent the linear best fit
1

regression for PPR (orange) and CV2 (purple). For all graphs, the horizontal line represents
the time and duration of drug application. Data are mean ± s.e.m.
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Figure 3-10: Blocking EP4 receptor abolishes potentiation after acute restraint stress.
16

(A) An example of a typical eIPSC recording in an acutely restrained mouse, comparing
baseline EP4 antagonist (black) and after PGE2 agonist (red) application. (B) Individual timecourse of eIPSC 1 amplitude. (C) Summary time-course of normalized eIPSC 1 amplitude,
1

1

PPR, and CV2. (D) Correlation plot of eIPSC (% baseline) with PPR (orange) or CV2 (purple)
after treatment with PGE2 during EP4 antagonist. The lines represent the linear best fit
1

regression for PPR (orange) and CV2 (purple). For all graphs, the horizontal line represents
the time and duration of drug application. Data are mean ± s.e.m.
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3.9 Blocking EP1 receptor mimics acute psychosocial stress
Potentiation could arise due to the activation of EP2 and EP4 receptors by PGE2 application
post-stress, but this is not greater after stress as was observed with PGE 2. One possibility is
that EP2 and EP4-mediated potentiation is suppressed under naïve conditions and unmasked
by stress. It is unlikely that EP3 receptor suppresses EP2 and EP4-potentiation since blocking
EP3 did not unmask potentiation in naïve conditions. EP1 receptor is critical to the
inflammation response, as is evident since its knockout impairs LPS-induced HPA axis
activation (Matsuoka et al., 2003). Yet the effects of EP1 on the PVN-CRH neurons remains
unknown.
To examine potential roles of EP1 receptor in PGE2-mediated changes in GABAergic
synaptic transmission, we pharmacologically blocked EP1 receptor during PGE2 application.
In naïve animals, application of PGE2 in the presence of EP1 antagonist (GW 848687X, 1 µM
for recording duration) resulted in a heterogeneous response: in some recordings we observed
a depression of eIPSCs (49.51 ± 4.65% of baseline, p = 0.0004, n = 5 of 9) (Figure 3-11 A
[i], B, C) and others potentiation (151.70 ± 21.17% of baseline, p = 0.0925, n = 4 of 9)
(Figure 3-11 A [ii], B, C). These results somewhat mimic the effects of restraint stress which
caused depression (49.51 ± 4.65% of baseline vs. 42.90 ± 6.21% of baseline, p = 0.4831) and
potentiation (151.70 ± 21.17% of baseline vs. 135.67 ± 12.60% of baseline, p = 0.5767). The
proportion of neurons that were depressed (n = 5 of 9 [56%] vs. n = 9 of 13 [69%]) and
potentiated (n = 4 of 9 [44%] vs. n = 4 of 13 [31%]) is similar between EP1 antagonist naïve
conditions compared to PGE2 stress conditions.
In the naïve recordings that were depressed, there was a decrease in

1
CV2

(21.12 ± 7.92% of

baseline, p = 0.0006, n = 5) with no change in PPR (104.00 ± 17.77% of baseline, p =
0.8322, n = 5) (Figure 3-11 C, D). The lack of PPR change by PGE2 during EP1 antagonist,
by contrast to its robust increase by PGE2 in naïve conditions (104.00 ± 17.77% of baseline,
vs. 138.10 ± 9.62% of baseline, p = 0.0868) suggests that EP1 might be necessary to increase
PPR. Regarding sIPSCs, in the recordings that were depressed, PGE2 in the presence of EP1
antagonist decreased frequency (59.59 ± 4.77% of the baseline, p = 0.0011, n = 5) (Figure 311 E [i], G, H, I) with no change in amplitude (98.06 ± 4.569% of the baseline, p = 0.6936, n
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= 5) (Figure 3-11 E [i], F, H, I). This data is consistent with pre-synaptic EP3 receptormediated depression of GABA release. In recordings that were potentiated, there was no
1

change in PPR (109.90 ± 14.21% of baseline, p = 0.5352, n = 4), CV2 (94.80 ± 32.67% of
baseline, p = 0.8837, n = 4) (Figure 3-11 C, D), sIPSC frequency (98.56 ± 18.21% of the
baseline, p = 0.9418, n = 4) (Figure 3-11 E [ii], G, H, I), or amplitude (104.50 ± 8.58% of
the baseline, p = 0.6354, n = 4) (Figure 3-11 E [ii], F, H, I). The lack of change of any
synaptic properties in PGE2-induced potentiated traces was unexpected, failing to indicate
either pre- or post-synaptic locus, and we currently have no explanation for the results.
However, considering the low sample number (n = 4), it is likely that increasing the sample
number will provide clearer results.
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Figure 3-11: Blocking EP1 receptor causes some neurons to potentiate GABA
17

transmission on CRH neurons.
(A) An example of a typical eIPSC recording in a naïve mouse, comparing baseline EP1
antagonist (black) and after PGE2 (blue) application for a neuron that (i) depressed and (ii)
potentiated. (B) Individual time-course of eIPSC 1 amplitude. (C) Summary time-course of
1

normalized eIPSC 1 amplitude, PPR, and CV2 for the population of neurons that depressed
(dark) and potentiated (light). (D) Correlation plot of eIPSC (% baseline) with PPR (orange)
1

or CV2 (purple) after treatment with PGE2 during EP1 antagonist. The lines represent the
1

linear best fit regression for PPR (orange) and CV2 (purple) for the population of neurons that
depressed (dark) and potentiated (light). (E) An example of a typical sIPSC recording in a
naïve mouse, comparing baseline EP1 antagonist (black) and after PGE2 (blue) application
for a neuron that (i) depressed and (ii) potentiated. (F) Individual time-course of sIPSC
frequency and (G) sIPSC amplitude. (H) Summary time-course of normalized sIPSC
frequency (orange) and amplitude (purple) for the population of neurons that depressed
(dark) and potentiated (light). (I) Correlation plot of eIPSC (% baseline) with sIPSC
frequency (orange) or amplitude (purple) after treatment with PGE2 during EP1 antagonist.
The lines represent the linear best fit regression for sIPSC frequency (orange) or amplitude
(purple) for the population of neurons that depressed (dark) and potentiated (light). For all
graphs, the horizontal line represents the time and duration of drug application. Data are
mean ± s.e.m.
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3.9.1 Blocking EP1 receptor after stress shifts balance of
depression/potentiation to potentiation
After restraint stress the application of PGE2 during EP1 antagonist resulted a mixture of
eIPSCs that depress (74.36 ± 2.72% of baseline, p = 0.0672, n = 2 of 6) (Figure 3-12 A [i],
B, C) and potentiate (146.50 ± 11.00% of baseline, p = 0.0242, n = 4 of 6) (Figure 3-12 A
[ii], B, C). Interestingly, the balance of depression: potentiation after stress and EP 1
antagonist has further shifted towards potentiation after stress compared to EP1 antagonist
applied in naïve conditions (n = 4 of 6 [67%] vs. n = 4 of 9 [44%]), in line with the
suggestion that EP1 is downregulated by stress to release potentiation.
In restraint stress recordings that depressed there was no change in PPR (140.90 ± 21.80% of
baseline, p = 0.3120, n = 2) or

1
CV2

(64.44 ± 27.78% of baseline, p = 0.4222, n = 2) (Figure 3-

12 C, D). In traces that depress eIPSCs, the sIPSC analysis showed that PGE 2 application
with EP1 antagonist trends to decrease frequency (47.03 ± 8.80% of the baseline, p = 0.1048,
n = 2) (Figure 3-12 E [i], G, H, I) with no change in amplitude (85.34 ± 4.87% of the
baseline, p = 0.2040, n = 2) (Figure 3-12 E [i], F, H, I). Again, like in naïve conditions, the
lack of synaptic properties changing suggests that it is other EP receptors (such as EP 3) that
alter synaptic properties during depression.
In recordings of eIPSCs which potentiated there was no change in PPR (93.80 ± 11.93% of
1

baseline, p = 0.63.91, n = 4) or CV2 (123.10 ± 20.64% of baseline, p = 0.3448, n = 4) (Figure
3-12 C, D). sIPSC analysis revealed does not change frequency (92.52 ± 28.97% of the
baseline, p = 0.8130, n = 4) (Figure 3-12 E [i], G, H, I) or amplitude (110.10 ± 8.95% of the
baseline, p = 0.3399, n = 4) (Figure 3-12 E [i], F, H, I). Similar to the case with the naïve
slices, the lack of change of any synaptic properties in PGE 2-induced potentiated traces was
unexpected, and we currently have no explanation for the results. However, considering the
low sample number (n = 4), it is likely that increasing sample number will provide clearer
results.
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Figure 3-12: Acute stress continues to shift EP1 receptor antagonization to potentiation
18

of GABA transmission on CRH neurons.
(A) An example of a typical eIPSC recording in an acutely restrained mouse, comparing
baseline EP1 antagonist (black) and after PGE2 (red) application for a neuron that (i)
depressed and (ii) potentiated. (B) Individual time-course of eIPSC 1 amplitude. (C)
1

Summary time-course of normalized eIPSC 1 amplitude, PPR, and CV2 for the population of
neurons that depressed (dark) and potentiated (light). (D) Correlation plot of eIPSC (%
1

baseline) with PPR (orange) or CV2 (purple) after treatment with PGE2 during EP1 antagonist.
1

The lines represent the linear best fit regression for PPR (orange) and CV2 (purple) for the
population of neurons that depressed (dark) and potentiated (light). (E) An example of a
typical sIPSC recording in an acutely restrained mouse, comparing baseline EP 1 antagonist
(black) and after PGE2 (red) application for a neuron that (i) depressed and (ii) potentiated.
(F) Individual time-course of sIPSC frequency and (G) sIPSC amplitude. (H) Summary timecourse of normalized sIPSC frequency (orange) and amplitude (purple) for the population of
neurons that depressed (dark) and potentiated (light). (I) Correlation plot of eIPSC (%
baseline) with sIPSC frequency (orange) or amplitude (purple) after treatment with PGE2
during EP1 antagonist. The lines represent the linear best fit regression for sIPSC frequency
(orange) or amplitude (purple) for the population of neurons that depressed (dark) and
potentiated (light). For all graphs, the horizontal line represents the time and duration of drug
application. Data are mean ± s.e.m.
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Chapter 4
4 Discussion
This thesis examined synaptic mechanisms with relevance to the immune-induced activation
of the HPA axis and their modulation by psychological stress. In Aim 1 and 2, we replicated
key findings, which we had made previously in rats (Khazaeipool et al., 2018), in mice.
Specifically, we showed that PGE2 suppressed the synaptic release of GABA onto PVNCRH neurons in slices from (normal) unstressed mice, and that this PGE2 effect was
mediated by EP3 receptor (Aim 1). We also showed that an exposure to a psychological stress
(prior to brain slice preparation) made the PGE2 effects on GABA release heterogeneous,
causing a potentiation of GABA release in some, but not all, synapses (Aim 2). These results
showed that the effects of PGE2 and their impairment by a psychological stressor (acute
restraint) are preserved between rats and mice. This transition to a mouse model is necessary
to take advantage of the CRH reporter line that can genetically identify CRH neurons in the
PVN. Previously in rats, we recorded from electrophysiologically characterized, putative
CRH neurons that include non-CRH neurons as well.
After establishing the mouse model, we sought to tease out the mechanisms underlying the
modulatory effects of psychological stress on the actions of PGE 2 (Aim 3). Our data revealed
function for the four different subtypes of EP receptors. First, EP3 receptor depressed the
release of GABA, which is intact after psychological stress. Second, EP2 and EP4 receptors
facilitated (conversely to EP3 receptor) the release of GABA onto PVN-CRH neurons, which
also was not altered by psychological stress. Third, in the presence of an EP1 receptor
antagonist in control (unstressed) slices, PGE2 caused heterogeneous changes in GABA
release similar to what was observed after psychological stress. Taken together, our data
suggested that EP1 receptor blocks EP2 and EP4 receptor-mediated potentiation in control
slices and an exposure to psychological stress downregulates EP1 receptors, allowing the
emergence of potentiation (Figure 4-1 A, B). Below, I will discuss the implications of these
findings in more detail.
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4.1 PGE2 suppresses GABAergic synaptic transmission on
CRH neurons via pre-synaptic EP3 receptor in mice
It is well documented that PGE2 mediates the activation of the HPA axis during systemic
inflammation (Morimoto et al., 1989; Rivier & Vale, 1991). One potential mechanism
through which PGE2 activates the HPA axis is the removal of tonic GABAergic inhibition
from CRH neurons (disinhibition) (Bains et al., 2015; Hewitt et al., 2009; Sarkar, Wakefield,
MacKenzie, Moss, & Maguire, 2011; Verkuyl, Hemby, & Joëls, 2004). For example, an
earlier work by Ferri and Ferguson (2003), showed that application of IL-1β, a cytokine that
stimulates the synthesis of PGE2 in the brain, or of PGE2 decreased the frequency of
spontaneous GABAergic synaptic transmission to PVN-PNCs (Ferri & Ferguson, 2003). A
recent study by our group found that PGE 2 potently depresses both evoked and spontaneous
release of GABA onto PVN-PNCs (Khazaeipool et al., 2018). Built on these findings, my
thesis examined the effects of PGE2 on the GABAergic synapses onto CRH neurons in
mouse using a CRH reporter line. In section 3.1, I showed that PGE2, in mouse, potently
inhibits the release of GABA onto PVN-CRH neurons with a rapid (< 5 min) onset and a
long-lasting effect (> 15 min), replicating a similar effect of PGE 2 observed in rats.
Matsuoka et al. had demonstrated that knocking out the EP3 receptor impaired the HPA axis
activation in response to LPS administration (Matsuoka et al., 2003), suggesting EP3 receptor
is essential in the inflammatory signaling path. Khazaeipool’s study specifically
demonstrated that PGE2 action was mediated by EP3 receptor in mouse (Khazaeipool et al.,
2018). In section 3.3, I showed that EP3 agonist mimics the effects of PGE2, with a decrease
in eIPSC amplitude of similar time-course, magnitude, and duration to that of PGE2,
suggesting that EP3 receptor mediates the effects of PGE2. My data suggest pre-synaptic loci
(Zucker & Regehr, 2002) for the actions of PGE2 and EP3 receptor. A pre-synaptic locus of
action for EP3 receptor is consistent with histological studies that show that EP3 receptor
proteins are expressed in the pre-synaptic axons terminating in the PVN (Nakamura et al.,
2000). Additionally, consistent with EP3 receptors operating in pre-synaptic GABA neurons,
an in situ hybridization study has localized EP3 mRNA in the BNST, the DMH, and the
POA, which are known to send GABAergic inputs to the PVN (Ek et al., 2000). My data
extend previous findings of the action of PGE2 in the PVN (Ferri & Ferguson, 2003; Ferri et
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al., 2005; Khazaeipool et al., 2018) and show that PGE2 actions are preserved between rats
and mice.

4.2 Restraint stress impairs PGE2-mediated suppression of
GABA release
Several studies have suggested that prior stress alters immune-induced activation of the HPA
axis. For example, repeated restraint stress attenuated the rise of ACTH and CORT induced
by LPS given one day after the last restraint stress in rats (Gadek-Michalska et al., 2005). On
the other hand, another study found a sensitization of the LPS-induced ACTH and CORT
response after a single inescapable tail shock (Johnson et al., 2002). These results pointed to
the possibility that an exposure to one stressor can modulate – increase or decrease –
subsequent HPA activation by a different stressor. How this type of HPA axis modulation
occurs remains unclear. My thesis found that acute restraint stress reduced PGE2-mediated
suppression of GABAergic synaptic transmission. I then examined the underlying
mechanisms for this modulation.

4.3 Mechanism for restraint stress altering PGE2 suppression
of GABA
4.3.1 EP3-mediated depression of GABA release is intact after
stress
In naïve mouse PVN, as discussed in section 4.1, PGE2 acts through EP3 receptor and
decreases the release of GABA from the pre-synaptic terminal. EP3 receptor is coupled to
Gαi/o, which decreases cAMP and commonly decreases neurotransmitter release (Atwood et
al., 2014) from the pre-synaptic terminal. In the PVN, it has been reported that CB1 receptor,
a Gαi/o coupled receptor, depresses GABA release and that repeated restraint stress
downregulates CB1 thereby impairing the CB1-mediated inhibition of GABA release. Thus,
we initially hypothesized that an acute restraint stress would down-regulate EP3 receptor and
consequently would impair PGE2-mediated inhibition of GABA release. However, our
results did not support this hypothesis, instead revealing that pharmacological stimulation of
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EP3 receptor resulted in a reduction of GABA release in a virtually identical manner both in
slices from normal and stressed mice.

4.3.2 EP2 and EP4 receptors potentiate GABA release and are
intact after stress
In addition to the effects of EP3 receptor in depressing the release of GABA, we revealed that
the activation of EP2 and EP4 causes potentiation of GABA release. Specifically, we found
that co-application of specific EP2 and EP4 agonists potentiated eIPSC amplitude. The
1

potentiation was accompanied by an increase of CV2 with little changes in PPR, indicating
that EP2/EP4 receptor activation increased the number of functional synapses releasing
GABA. To our knowledge, this is the first demonstration that EP2 and EP4 receptors
modulate synaptic functions in the PVN. Mechanistically, EP2 and EP4 receptors are coupled
to Gαs and increase cAMP (opposite to Gαi/o-coupled EP3) (Narumiya et al., 1999), explaining
how these receptors resulted in an increase of GABA release.
Application of an antagonist for EP2 or EP4 abolished the PGE2-mediated potentiation after
psychological stress. That all potentiation was removed by blocking either EP2 receptor or
EP4 receptor suggests that the two might be co-dependent; thus, we conclude that it is
essential to have both EP2 receptor and EP4 receptor for potentiation.
In naive conditions, PGE2 application (i.e. activation of all EP1-4 receptors) results in the presynaptic inhibition of GABA release, indicating that the EP3-mediated mechanism overrides
the EP2- and EP4-mediated potentiation. It is only after an acute restraint stress that we found
GABA synapse potentiation in some, but not all, synapses. Thus, we next hypothesized that
restraint stress upregulates EP2 and EP4 receptors at some synapses, causing potentiation,
even in the presence of EP3 receptor. However, agonist experiments found that restraint
stress did not enhance EP2 and EP4 receptor-mediated potentiation.
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4.3.3 EP1 receptor gates EP2 and EP4 receptor-mediated
potentiation
In slices from naïve mice, we found that the blockade of EP1 receptor during PGE2
application mimics the effects of acute restraint stress, resulting in a potentiation of a subset
of GABA synapses. Since EP3-mediated depression predominated over EP2/EP4-mediated
potentiation of naïve GABA synapses on PVN-CRH neurons, our current working hypothesis
is that EP1 receptor inhibits EP2/EP4 receptors in naïve PVN. When EP1 receptor is
pharmacologically blocked, it unmasks the competition between EP 3 and EP2/EP4 receptors:
some synapses become potentiated by EP2/EP4 receptor activity. Acute restraint stress
downregulates the gating by EP1 receptors, unmasking the EP2/EP4 receptor-mediated
potentiation. Consistent with acute restraint stress downregulating EP1 receptor, EP1
antagonist application to slices from psychologically stressed mice did not further cause
potentiation (i.e. occlusion). This proposed mechanism is consistent with the heterogenous
response observed due to PGE2 application after restraint stress (where distinct populations
potentiate and depresses): populations that depress lack EP2/EP4 receptor activity (necessary
for potentiation) (Figure 4-1 C, D), while those that potentiate post-stress must contain at
least EP2/EP4 and EP1 receptors (Figure 4-1 A, B). An earlier EP receptor KO mice study
showed that EP1 receptor-, in addition to EP3 receptor-, deficient mice showed an impaired
HPA axis response to systemic LPS administration (Matsuoka et al., 2003), suggesting that
both EP1 and EP3 are necessary for PGE2-mediated activation of the HPA axis and aligned
with this thesis’s results.
In situ hybridization found EP1 receptor mRNA expression in the ventromedial preoptic
nucleus, the median preoptic nucleus, and the PVN (Oka et al., 2000). On the other hand,
major GABAergic inputs to the PVN originate from the anterior paraventricular nucleus, the
anterior perifornical area, anterior hypothalamic, and dorsomedial hypothalamic nucleus
(Cullinan et al., 2008; Roland & Sawchenko, 1993). Given that localization of EP1 receptor
mRNA do not correspond with the major GABA inputs, currently there is no evidence to
support the expression of EP1 receptor in the pre-synaptic terminals of the GABA synapses
onto PVN-CRH neurons.
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The neuronal mechanisms downstream of EP1 receptor activation remain largely unknown.
EP1 receptor is a GPCR coupled with Gαq, as was briefly discussed in section 1.8. Gαq can
stimulate PI3K for many downstream effects. Some of these downstream effects of PI3K are
to cause PIP2 metabolism, leading to the formation of IP3 and DAG. IP3 increases
intracellular Ca2+ level which can influence vesicle release, while DAG activates PKC for
feedback regulation on EP1 and other EP receptors (Narumiya et al., 1999). Gαq signaling has
also been shown to increase intracellular levels of Cl - through down-regulation of potassium
chloride co-transporter (KCC)2 that typically establishes the Cl- gradient that makes GABA
inhibitory. Rises of intracellular Cl- could lead to GABA signaling excitatory (Inoue &
Bains, 2014). Since our data suggest that EP1 receptor is located post-synaptically, then to
regulate pre-synaptic EP2 and EP4 receptor, Gq signaling must act retrogradely across the
synapse. How EP1 receptor signaling inhibits EP2/EP4 requires future study.

4.4 Potential purpose of an EP1 receptor-mediated mechanism
EP1 receptor has a lower affinity of binding to PGE2 than any other EP receptor (Oka et al.,
2000), which may endow a wide dynamic range of HPA axis activity by PGE2, such that
various concentrations of PGE2 can promote a range of responses, from mild to severe
inflammation. The physiological roles of EP2 and EP4 signaling in the PVN remains
unknown. EP2 and EP4 receptor KO mice showed an intact HPA axis activation after LPS
challenge (Matsuoka et al., 2003). However, it remains to be examined if and how
psychological stress alters the immune (LPS)-induced HPA axis activation in EP2/EP4
receptor deficient mice. Beyond the HPA axis, EP4 receptor in the PVN has been implicated
in anorexic response to inflammation (Ohinata, Suetsugu, Fujiwara, & Yoshikawa, 2006).

4.5 Limitations and future directions
This M.Sc. thesis demonstrates a plausible mechanism for acute psychological stress altering
the GABA synaptic transmission on PVN-CRH neurons with relevance to the HPA axis
activation (Figure 4-1 A, B). My data pointed to a potential model that EP1 receptor prevents
the potentiation of GABA release by EP2 and EP4 receptors, thus indirectly contributing to
EP3-mediated inhibition of GABA release. Along this line, we speculate that acute stress
down-regulates EP1 receptor, unmasking EP2/EP4-mediated potentiation. However, many

82
questions need to be tested to prove our working model. I will briefly explore types of
experiments that need to be done in the future as well as alternative explanations to our
current working hypothesis.

4.5.1 Actions of EP1
As a next step to test our working model, we should co-apply agonists for EP1, EP2 and EP4.
If our model is correct, EP1 agonist will block the potentiation caused by EP2/EP4 agonists.
Further studies might assess if EP1 receptor is altered by stress.
This action of EP1 appears to be due to the post-synaptic actions of EP1 receptor, by contrast
to the pre-synaptic effects of other EP receptors on GABA synapse transmission. The
mechanism of post-synaptic action of EP1 receptor leading to the potentiation of eIPSCs
remains unknown. However, one potential mechanism is that EP1 receptor activation alters
Cl- homeostasis in the post-synaptic neuron. GABAA receptors are ligand-gated ion channels,
which selectively conduct Cl- down their electrochemical gradient. In adult neurons, low
intracellular Cl- causes Cl- influx through GABAA receptors at resting membrane potential
(reversal potential = -70 mV), which causes hyperpolarization of the post-synaptic membrane
(Olsen & DeLorey, 1999; Wu & Sun, 2015). Low intracellular Cl- is primarily achieved by
the active extrusion of Cl- by KCC2 (Farrant & Kaila, 2007). Gq-coupled receptors have been
shown to increase intracellular levels of Cl- through down-regulation of KCC2, which alters
the Cl- gradient such that GABAA receptor signaling is less inhibitory or even excitatory
(Inoue & Bains, 2014; Nabekura et al., 2002; Pathak et al., 2007). If EP1 receptor
downregulates KCC2 post-synaptically, this would potentiate the eIPSC amplitude in our
experimental conditions that record IPSCs by holding the post-synaptic neurons at -80 mV.
To probe whether PGE2, via EP1, downregulates KCC2 to increase the intracellular Cl- levels
in PVN-CRH neurons, future experiments may measure if there is an alteration of the
GABAA receptor reversal potential using patch-clamp electrophysiology.

4.5.2 Psychological stress may alter EP3 receptor functions
While our results showed no effects of acute psychological stress on EP 3 receptor-mediated
depression of GABA synapse transmission, it is important to acknowledge that this
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experiment was done with only one concentration of EP3 receptor agonist. It is possible that
the dose we used (1 µM) saturated the effects of EP3 receptor and masked potential effects of
psychological stress altering EP3 receptor functions. In line with this, EP3 receptor has a
greater affinity for PGE2 than the other EP receptors (Coleman et al., 1994; Oka et al., 2000).
Conducting a dose-response curve for EP3 agonist before and after an acute stress will clarify
if stress modulates EP3-mediated depression.

4.5.3 The origins of EP3-expressing GABAergic inputs on CRH
neurons
Our data replicate previous findings that pre-synaptic EP3 receptors suppress the release of
GABA from GABAergic neurons projecting to the PVN. It is apparent both in our data in
mice and rats (Khazaeipool et al., 2018) that there is heterogeneity in the response to PGE2.
The origins of GABA inputs to PVN include: anterior hypothalamus (AH), DMH and the
anterior perifornical area (part of the BNST) (Roland & Sawchenko, 1993). Each of these
different inputs has different quantities of EP3 receptor, with the densest concentration being
the DMH and the least in the BNST (Ek et al., 2000; Nakamura et al., 2000). These different
GABA projections to the PVN containing different amounts of EP3 receptor may contribute
relatively differently to the PGE2-mediated depression. Injection of a virus for expression of
light-activated channelrhodospin 2 (optogenetics) into each of the nuclei of interest would
allow for an input-specific recording and examination of the sensitivity to PGE 2 and EP
receptor agonists. This would discriminate the different contributions of each GABA input
and potentially explain the intra-treatment heterogeneity.

4.5.4 PGE2 actions beyond GABA synapses
It is important to acknowledge that while I have suggested a mechanism affecting
GABAergic synaptic transmission, it is likely that non-GABAergic mechanisms are acting in
parallel in vivo. For example, the blockade of COX-1 and COX-2 for the synthesis of PGs
decreases NA-induced activation of the HPA axis, indicating that PGE 2 acts downstream of
NAergic signaling (Bugajski, 1996). Conversely, it has been shown that a COX inhibitor,
indomethacin, abolished IL-1β-induced NA release in the hypothalamus (Tsumori et al.,

84
1998), indicating that PGE2 modulates the release of NA. Future research is necessary to
investigate the actions of PGE2 besides GABA synapses.

4.6 Significance
One aspect of the immune response to inflammation involves the production of PGE 2, which
in turn activates the HPA axis (Narumiya & Furuyashiki, 2011). This immune-induced
activation of the HPA axis can be modulated by prior psychological stress (Gadek-Michalska
et al., 2005; Johnson et al., 2002). My research demonstrates a potential synaptic mechanism
for the stress-modulation of immune-induced HPA axis response.
Inflammation is one of our bodies defense mechanism against invading pathogens and
injuries. Most presentations to primary care involve stress and many diseases feature
inflammatory symptoms (Gluckman, Low, Buklijas, Hanson, & Beedle, 2011). GCs, as
potent immunosuppressants, produced by the HPA axis acts for effective resolution of
inflammation (Ruzek et al., 1999; Sapolsky et al., 2000). This negative feedback control of
inflammation is important to prevent overactive immune response (Silverman, Pearce, Biron,
& Miller, 2005). It is thus critical to understand how the brain, through the HPA axis,
regulates inflammation. Dysregulation of the HPA axis and thus of GC production is
implicated in abnormal and maladaptive inflammatory responses in diseases like sepsis
(Kotas & Medzhitov, 2015) and arthritis (Angus & Wax, 2001; Schroeder et al., 2001).
Advancing our understanding of the regulation of the immune-induced HPA axis and how it
is susceptible to stress will inform us of potential mechanisms for the dysregulation of the
HPA axis. Our findings on the synaptic mechanisms for HPA axis activation and how they
may be impacted by a history of stress shed a light on the mechanisms that may be altered in
disease conditions that involve an impaired HPA axis function.
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Figure 4-1: Schematic diagram of the proposed synaptic mechanism of inflammation19

induced activation of the HPA axis and its change after acute restraint stress.
In synapses that potentiate after stress, (A) in naïve conditions, PGE2 application causes
depression of GABA synaptic transmission on CRH neurons as EP1 receptor blocks EP2 and
EP4 receptor allowing pre-synaptic EP3 receptor to predominate; (B) in acute restraint stress
conditions, PGE2 application causes potentiation of GABA synaptic transmission on CRH
neurons as post-synaptic EP1 receptor is downregulated, allowing pre-synaptic EP2 and EP4
receptor potentiation to predominate. In synapses that depress after stress, PGE2 application
causes depression of GABA synaptic transmission on CRH neurons as via EP3 receptor (C)
before and (D) after stress, with no presence of EP2 and EP4 receptor.

86

References
Abramovitz, M., Adam, M., Boie, Y., Carrière, M., Denis, D., Godbout, C., … Metters, K.
M. (2000). The utilization of recombinant prostanoid receptors to determine the
affinities and selectivities of prostaglandins and related analogs. Biochimica Et
Biophysica Acta, 1483(2), 285–293.
Aderem, A., & Ulevitch, R. J. (2000). Toll-like receptors in the induction of the innate
immune response. Nature, 406(6797), 782–787. https://doi.org/10.1038/35021228
af Forselles, K. J., Root, J., Clarke, T., Davey, D., Aughton, K., Dack, K., & Pullen, N.
(2011). In vitro and in vivo characterization of PF-04418948, a novel, potent and
selective prostaglandin EP₂ receptor antagonist. British Journal of Pharmacology,
164(7), 1847–1856. https://doi.org/10.1111/j.1476-5381.2011.01495.x
Aguilera, G., & Rabadan-Diehl, C. (2000). Regulation of vasopressin V 1b receptors in the
anterior pituitary gland of the rat. Experimental Physiology, 85(s1), 19s–26s.
https://doi.org/10.1111/j.1469-445X.2000.tb00004.x
Alexander, C., & Rietschel, E. T. (2001). Bacterial lipopolysaccharides and innate immunity.
Journal of Endotoxin Research, 7(3), 167–202.
Angus, D. C., & Wax, R. S. (2001). Epidemiology of sepsis: an update. Critical Care
Medicine, 29(7 Suppl), S109-116.
Atwood, B. K., Lovinger, D. M., & Mathur, B. N. (2014). Presynaptic long-term depression
mediated by Gi/o-coupled receptors. Trends in Neurosciences, 37(11), 663–673.
https://doi.org/10.1016/j.tins.2014.07.010
Bains, J. S., Wamsteeker Cusulin, J. I., & Inoue, W. (2015). Stress-related synaptic plasticity
in the hypothalamus. Nature Reviews. Neuroscience, 16(7), 377–388.
https://doi.org/10.1038/nrn3881

87
Barton, G. M. (2008). A calculated response: control of inflammation by the innate immune
system. The Journal of Clinical Investigation, 118(2), 413–420.
https://doi.org/10.1172/JCI34431
Benarroch, E. E. (2005). Paraventricular nucleus, stress response, and cardiovascular disease.
Clinical Autonomic Research: Official Journal of the Clinical Autonomic Research
Society, 15(4), 254–263. https://doi.org/10.1007/s10286-005-0290-7
Berghorn, K. A., Knapp, L. T., Hoffman, G. E., & Sherman, T. G. (1995). Induction of
glucocorticoid receptor expression in hypothalamic magnocellular vasopressin
neurons during chronic hypoosmolality. Endocrinology, 136(2), 804–807.
https://doi.org/10.1210/en.136.2.804
Biag, J., Huang, Y., Gou, L., Hintiryan, H., Askarinam, A., Hahn, J. D., … Dong, H.-W.
(2012). Cyto- and chemoarchitecture of the hypothalamic paraventricular nucleus in
the C57BL/6J male mouse: a study of immunostaining and multiple fluorescent tract
tracing. The Journal of Comparative Neurology, 520(1), 6–33.
https://doi.org/10.1002/cne.22698
Bittar, T. P., Nair, B. B., Kim, J. S., Chandrasekera, D., Sherrington, A., & Iremonger, K. J.
(2019). Corticosterone mediated functional and structural plasticity in corticotropinreleasing hormone neurons. Neuropharmacology.
https://doi.org/10.1016/j.neuropharm.2019.02.017
Blanks, A. M., & Thornton, S. (2003). The role of oxytocin in parturition. BJOG: An
International Journal of Obstetrics and Gynaecology, 110 Suppl 20, 46–51.
Blatteis, C. M. (2007). The onset of fever: new insights into its mechanism. Progress in
Brain Research, 162, 3–14. https://doi.org/10.1016/S0079-6123(06)62001-3

88
Bliss, T. V., & Collingridge, G. L. (1993). A synaptic model of memory: long-term
potentiation in the hippocampus. Nature, 361(6407), 31–39.
https://doi.org/10.1038/361031a0
Blitz, D. M., Foster, K. A., & Regehr, W. G. (2004). Short-term synaptic plasticity: a
comparison of two synapses. Nature Reviews. Neuroscience, 5(8), 630–640.
https://doi.org/10.1038/nrn1475
Bradbury, M. W., & Davson, H. (1965). The transport of potassium between blood,
cerebrospinal fluid and brain. The Journal of Physiology, 181(1), 151–174.
https://doi.org/10.1113/jphysiol.1965.sp007752
Branco, T., & Staras, K. (2009). The probability of neurotransmitter release: variability and
feedback control at single synapses. Nature Reviews. Neuroscience, 10(5), 373–383.
https://doi.org/10.1038/nrn2634
Breder, C. D., & Saper, C. B. (1996). Expression of inducible cyclooxygenase mRNA in the
mouse brain after systemic administration of bacterial lipopolysaccharide. Brain
Research, 713(1–2), 64–69.
Bugajski, J. (1996). Role of prostaglandins in the stimulation of the hypothalamic-pituitaryadrenal axis by adrenergic and neurohormone systems. Journal of Physiology and
Pharmacology : An Official Journal of the Polish Physiological Society, 47(4), 559–
575.
Buller, K., Xu, Y., Dayas, C., & Day, T. (2001). Dorsal and ventral medullary catecholamine
cell groups contribute differentially to systemic interleukin-1beta-induced
hypothalamic pituitary adrenal axis responses. Neuroendocrinology, 73(2), 129–138.
https://doi.org/10.1159/000054629

89
Cao, C., Matsumura, K., Yamagata, K., & Watanabe, Y. (1996). Endothelial cells of the rat
brain vasculature express cyclooxygenase-2 mRNA in response to systemic
interleukin-1 beta: a possible site of prostaglandin synthesis responsible for fever.
Brain Research, 733(2), 263–272.
Ceccatelli, S., Villar, M. J., Goldstein, M., & Hökfelt, T. (1989). Expression of c-Fos
immunoreactivity in transmitter-characterized neurons after stress. Proceedings of the
National Academy of Sciences of the United States of America, 86(23), 9569–9573.
Chrousos, G. P. (2000). The role of stress and the hypothalamic–pituitary–adrenal axis in the
pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related
causes (p. S50) [Report]. https://doi.org/10.1038/sj.ijo.0801278
Chrousos, George P. (2009). Stress and disorders of the stress system. Nature Reviews.
Endocrinology, 5(7), 374–381. https://doi.org/10.1038/nrendo.2009.106
Chrousos, George P., & Kino, T. (2007). Glucocorticoid action networks and complex
psychiatric and/or somatic disorders. Stress, 10(2), 213–219.
https://doi.org/10.1080/10253890701292119
Chu, X., Zhou, Y., Hu, Z., Lou, J., Song, W., Li, J., … Li, W. (2016). 24-hour-restraint stress
induces long-term depressive-like phenotypes in mice. Scientific Reports, 6, 32935.
https://doi.org/10.1038/srep32935
Colaianna, M., Schiavone, S., Zotti, M., Tucci, P., Morgese, M. G., Bäckdahl, L., …
Trabace, L. (2013). Neuroendocrine profile in a rat model of psychosocial stress:
relation to oxidative stress. Antioxidants & Redox Signaling, 18(12), 1385–1399.
https://doi.org/10.1089/ars.2012.4569
Cole, R. L., & Sawchenko, P. E. (2002). Neurotransmitter regulation of cellular activation
and neuropeptide gene expression in the paraventricular nucleus of the hypothalamus.

90
The Journal of Neuroscience: The Official Journal of the Society for Neuroscience,
22(3), 959–969.
Coleman, R. A., Smith, W. L., & Narumiya, S. (1994). International Union of Pharmacology
classification of prostanoid receptors: properties, distribution, and structure of the
receptors and their subtypes. Pharmacological Reviews, 46(2), 205–229.
Contarino, A., Dellu, F., Koob, G. F., Smith, G. W., Lee, K.-F., Vale, W., & Gold, L. H.
(1999). Reduced anxiety-like and cognitive performance in mice lacking the
corticotropin-releasing factor receptor 11Published on the World Wide Web on 27
November 1998.1. Brain Research, 835(1), 1–9. https://doi.org/10.1016/S00068993(98)01158-5
Contreras, R. G., Shoshani, L., Flores-Maldonado, C., Lázaro, A., & Cereijido, M. (1999).
Relationship between Na(+),K(+)-ATPase and cell attachment. Journal of Cell
Science, 112 ( Pt 23), 4223–4232.
Cullinan, W. E., Ziegler, D. R., & Herman, J. P. (2008). Functional role of local GABAergic
influences on the HPA axis. Brain Structure & Function, 213(1–2), 63–72.
https://doi.org/10.1007/s00429-008-0192-2
Cunningham, E. T., & Sawchenko, P. E. (1991). Reflex control of magnocellular vasopressin
and oxytocin secretion. Trends in Neurosciences, 14(9), 406–411.
Cusulin, J. I. W., Füzesi, T., Watts, A. G., & Bains, J. S. (2013). Characterization of
Corticotropin-Releasing Hormone neurons in the Paraventricular Nucleus of the
Hypothalamus of Crh-IRES-Cre Mutant Mice. PLOS ONE, 8(5), e64943.
https://doi.org/10.1371/journal.pone.0064943
Dayas, C. V., Buller, K. M., Crane, J. W., Xu, Y., & Day, T. A. (2001). Stressor
categorization: acute physical and psychological stressors elicit distinctive

91
recruitment patterns in the amygdala and in medullary noradrenergic cell groups. The
European Journal of Neuroscience, 14(7), 1143–1152.
de Kloet, E. R., Joëls, M., & Holsboer, F. (2005). Stress and the brain: from adaptation to
disease. Nature Reviews. Neuroscience, 6(6), 463–475.
https://doi.org/10.1038/nrn1683
De Kloet, E. R., & Reul, J. M. (1987). Feedback action and tonic influence of corticosteroids
on brain function: a concept arising from the heterogeneity of brain receptor systems.
Psychoneuroendocrinology, 12(2), 83–105.
Delpire, E., & Staley, K. J. (2014). Novel determinants of the neuronal Cl− concentration.
The Journal of Physiology, 592(Pt 19), 4099–4114.
https://doi.org/10.1113/jphysiol.2014.275529
Dickerson, S. S., & Kemeny, M. E. (2004). Acute stressors and cortisol responses: a
theoretical integration and synthesis of laboratory research. Psychological Bulletin,
130(3), 355–391. https://doi.org/10.1037/0033-2909.130.3.355
Dohanics, J., Hoffman, G. E., & Verbalis, J. G. (1996). Chronic hyponatremia reduces
survival of magnocellular vasopressin and oxytocin neurons after axonal injury.
Journal of Neuroscience, 16(7), 2373–2380. https://doi.org/10.1523/JNEUROSCI.1607-02373.1996
Dubois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., Van De Putte, L.
B., & Lipsky, P. E. (1998). Cyclooxygenase in biology and disease. FASEB Journal:
Official Publication of the Federation of American Societies for Experimental
Biology, 12(12), 1063–1073.
Edwards, R. H. (2007). The neurotransmitter cycle and quantal size. Neuron, 55(6), 835–858.
https://doi.org/10.1016/j.neuron.2007.09.001

92
Ek, M., Arias, C., Sawchenko, P., & Ericsson-Dahlstrand, A. (2000). Distribution of the EP3
prostaglandin E(2) receptor subtype in the rat brain: relationship to sites of
interleukin-1-induced cellular responsiveness. The Journal of Comparative
Neurology, 428(1), 5–20.
Elander, L., Engström, L., Ruud, J., Mackerlova, L., Jakobsson, P.-J., Engblom, D., …
Blomqvist, A. (2009). Inducible Prostaglandin E2 Synthesis Interacts in a Temporally
Supplementary Sequence with Constitutive Prostaglandin-Synthesizing Enzymes in
Creating the Hypothalamic–Pituitary–Adrenal Axis Response to Immune Challenge.
Journal of Neuroscience, 29(5), 1404–1413.
https://doi.org/10.1523/JNEUROSCI.5247-08.2009
Elenkov, null, & Chrousos, null. (1999). Stress Hormones, Th1/Th2 patterns, Pro/Antiinflammatory Cytokines and Susceptibility to Disease. Trends in Endocrinology and
Metabolism: TEM, 10(9), 359–368.
Elliott, K. a. C., & Flow, E. (1956). Factor I—Inhibitory Factor from Brain. Journal of
Neurochemistry, 1(2), 181–191. https://doi.org/10.1111/j.1471-4159.1956.tb12071.x
Faber, D. S., & Korn, H. (1991). Applicability of the coefficient of variation method for
analyzing synaptic plasticity. Biophysical Journal, 60(5), 1288–1294.
Faravelli, C., Lo Sauro, C., Lelli, L., Pietrini, F., Lazzeretti, L., Godini, L., … Ricca, V.
(2012). The role of life events and HPA axis in anxiety disorders: a review. Current
Pharmaceutical Design, 18(35), 5663–5674.
Farrant, M., & Kaila, K. (2007). The cellular, molecular and ionic basis of GABA(A)
receptor signalling. Progress in Brain Research, 160, 59–87.
https://doi.org/10.1016/S0079-6123(06)60005-8

93
Ferri, C. C., & Ferguson, A. V. (2003). Interleukin-1 beta depolarizes paraventricular nucleus
parvocellular neurones. Journal of Neuroendocrinology, 15(2), 126–133.
Ferri, Catharine C., Yuill, E. A., & Ferguson, A. V. (2005). Interleukin-1beta depolarizes
magnocellular neurons in the paraventricular nucleus of the hypothalamus through
prostaglandin-mediated activation of a non selective cationic conductance.
Regulatory Peptides, 129(1–3), 63–71. https://doi.org/10.1016/j.regpep.2005.01.004
Finsterwald, C., & Alberini, C. M. (2014). Stress and glucocorticoid receptor-dependent
mechanisms in long-term memory: from adaptive responses to psychopathologies.
Neurobiology of Learning and Memory, 112, 17–29.
https://doi.org/10.1016/j.nlm.2013.09.017
Fioravante, D., & Regehr, W. G. (2011). Short-term forms of presynaptic plasticity. Current
Opinion in Neurobiology, 21(2), 269–274. https://doi.org/10.1016/j.conb.2011.02.003
Flak, J. N., Solomon, M. B., Jankord, R., Krause, E. G., & Herman, J. P. (2012).
Identification of chronic stress-activated regions reveals a potential recruited circuit in
rat brain. The European Journal of Neuroscience, 36(4), 2547–2555.
https://doi.org/10.1111/j.1460-9568.2012.08161.x
Foy, M. R., Stanton, M. E., Levine, S., & Thompson, R. F. (1987). Behavioral stress impairs
long-term potentiation in rodent hippocampus. Behavioral and Neural Biology, 48(1),
138–149.
Furuyashiki, T., & Narumiya, S. (2009). Roles of prostaglandin E receptors in stress
responses. Current Opinion in Pharmacology, 9(1), 31–38.
https://doi.org/10.1016/j.coph.2008.12.010

94
Furuyashiki, Tomoyuki, & Narumiya, S. (2011). Stress responses: the contribution of
prostaglandin E(2) and its receptors. Nature Reviews. Endocrinology, 7(3), 163–175.
https://doi.org/10.1038/nrendo.2010.194
Gadek-Michalska, A., Spyrka, J., & Bugajski, J. (2005). Psychosocial stress affects the
involvement of prostaglandins and nitric oxide in the lipopolysaccharide-induced
hypothalamic-pituitary-adrenal response. Journal of Physiology and Pharmacology:
An Official Journal of the Polish Physiological Society, 56(2), 287–298.
Galic, M. A., Riazi, K., & Pittman, Q. J. (2012). Cytokines and brain excitability. Frontiers
in Neuroendocrinology, 33(1), 116–125. https://doi.org/10.1016/j.yfrne.2011.12.002
García-Bueno, B., Serrats, J., & Sawchenko, P. E. (2009). Cerebrovascular cyclooxygenase-1
expression, regulation, and role in hypothalamic-pituitary-adrenal axis activation by
inflammatory stimuli. The Journal of Neuroscience: The Official Journal of the
Society for Neuroscience, 29(41), 12970–12981.
https://doi.org/10.1523/JNEUROSCI.2373-09.2009
Gassmann, M., & Bettler, B. (2012). Regulation of neuronal GABA(B) receptor functions by
subunit composition. Nature Reviews. Neuroscience, 13(6), 380–394.
https://doi.org/10.1038/nrn3249
Giblin, G. M. P., Bit, R. A., Brown, S. H., Chaignot, H. M., Chowdhury, A., Chessell, I. P.,
… Wilson, R. (2007). The discovery of 6-[2-(5-chloro-2-{[(2,4difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid,
GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the
treatment of inflammatory pain. Bioorganic & Medicinal Chemistry Letters, 17(2),
385–389. https://doi.org/10.1016/j.bmcl.2006.10.041

95
Gluckman, P. D., Low, F. M., Buklijas, T., Hanson, M. A., & Beedle, A. S. (2011). How
evolutionary principles improve the understanding of human health and disease.
Evolutionary Applications, 4(2), 249–263. https://doi.org/10.1111/j.17524571.2010.00164.x
Griffin, J. B. (1990). Psychological Disturbances of Vegetative Function. In H. K. Walker,
W. D. Hall, & J. W. Hurst (Eds.), Clinical Methods: The History, Physical, and
Laboratory Examinations (3rd ed.). Retrieved from
http://www.ncbi.nlm.nih.gov/books/NBK318/
Guyre, P. M. (1998). Encyclopedia of Immunology | ScienceDirect. Retrieved February 26,
2019, from
https://www.sciencedirect.com/referencework/9780122267659/encyclopedia-ofimmunology
Hammen, C., Kim, E. Y., Eberhart, N. K., & Brennan, P. A. (2009). Chronic and acute stress
and the prediction of major depression in women. Depression and Anxiety, 26(8),
718–723. https://doi.org/10.1002/da.20571
Hashimoto, H., Matsuura, T., & Ueta, Y. (2014). Fluorescent visualization of oxytocin in the
hypothalamo-neurohypophysial system. Frontiers in Neuroscience, 8.
https://doi.org/10.3389/fnins.2014.00213
Hatae, N., Sugimoto, Y., & Ichikawa, A. (2002). Prostaglandin receptors: advances in the
study of EP3 receptor signaling. Journal of Biochemistry, 131(6), 781–784.
Hench, P. S., Kendall, E. C., Slocumb, C. H., & Polley, H. F. (1949). Adrenocortical
Hormone in Arthritis *. Annals of the Rheumatic Diseases, 8(2), 97–104.
Herman, J. P., McKlveen, J. M., Solomon, M. B., Carvalho-Netto, E., & Myers, B. (2012).
Neural regulation of the stress response: glucocorticoid feedback mechanisms.

96
Brazilian Journal of Medical and Biological Research = Revista Brasileira De
Pesquisas Medicas E Biologicas, 45(4), 292–298.
Herman, James P, & Cullinan, W. E. (1997). Neurocircuitry of stress: central control of the
hypothalamo–pituitary–adrenocortical axis. Trends in Neurosciences, 20(2), 78–84.
https://doi.org/10.1016/S0166-2236(96)10069-2
Herman, James P., Figueiredo, H., Mueller, N. K., Ulrich-Lai, Y., Ostrander, M. M., Choi, D.
C., & Cullinan, W. E. (2003). Central mechanisms of stress integration: hierarchical
circuitry controlling hypothalamo-pituitary-adrenocortical responsiveness. Frontiers
in Neuroendocrinology, 24(3), 151–180.
Herman, James P., McKlveen, J. M., Ghosal, S., Kopp, B., Wulsin, A., Makinson, R., …
Myers, B. (2016). Regulation of the Hypothalamic-Pituitary-Adrenocortical Stress
Response. Comprehensive Physiology, 6(2), 603–621.
https://doi.org/10.1002/cphy.c150015
Hewitt, S. A., Wamsteeker, J. I., Kurz, E. U., & Bains, J. S. (2009). Altered chloride
homeostasis removes synaptic inhibitory constraint of the stress axis. Nature
Neuroscience, 12(4), 438–443. https://doi.org/10.1038/nn.2274
Inoue, W., & Bains, J. S. (2014). Beyond inhibition: GABA synapses tune the
neuroendocrine stress axis. BioEssays: News and Reviews in Molecular, Cellular and
Developmental Biology, 36(6), 561–569. https://doi.org/10.1002/bies.201300178
Jezova, D., Skultetyova, I., Tokarev, D. I., Bakos, P., & Vigas, M. (1995). Vasopressin and
Oxytocin in Stressa. Annals of the New York Academy of Sciences, 771(1), 192–203.
https://doi.org/10.1111/j.1749-6632.1995.tb44681.x

97
Jiang, Z., Rajamanickam, S., & Justice, N. J. (2018). Local Corticotropin-Releasing Factor
Signaling in the Hypothalamic Paraventricular Nucleus. Journal of Neuroscience,
38(8), 1874–1890. https://doi.org/10.1523/JNEUROSCI.1492-17.2017
Johnson, E. O., Kamilaris, T. C., Chrousos, G. P., & Gold, P. W. (1992). Mechanisms of
stress: a dynamic overview of hormonal and behavioral homeostasis. Neuroscience
and Biobehavioral Reviews, 16(2), 115–130.
Johnson, J. D., O’Connor, K. A., Deak, T., Spencer, R. L., Watkins, L. R., & Maier, S. F.
(2002). Prior stressor exposure primes the HPA axis. Psychoneuroendocrinology,
27(3), 353–365.
Juteau, H., Gareau, Y., Labelle, M., Sturino, C. F., Sawyer, N., Tremblay, N., … Metters, K.
M. (2001). Structure-activity relationship of cinnamic acylsulfonamide analogues on
the human EP3 prostanoid receptor. Bioorganic & Medicinal Chemistry, 9(8), 1977–
1984. https://doi.org/10.1016/S0968-0896(01)00110-9
Kalinski, P. (2012). Regulation of immune responses by prostaglandin E2. Journal of
Immunology (Baltimore, Md.: 1950), 188(1), 21–28.
https://doi.org/10.4049/jimmunol.1101029
Kalsbeek, A., Bruinstroop, E., Yi, C. X., Klieverik, L. P., La Fleur, S. E., & Fliers, E. (2010).
Hypothalamic control of energy metabolism via the autonomic nervous system.
Annals of the New York Academy of Sciences, 1212, 114–129.
https://doi.org/10.1111/j.1749-6632.2010.05800.x
Katsuura, G., Arimura, A., Koves, K., & Gottschall, P. E. (1990). Involvement of organum
vasculosum of lamina terminalis and preoptic area in interleukin 1 beta-induced
ACTH release. The American Journal of Physiology, 258(1 Pt 1), E163-171.
https://doi.org/10.1152/ajpendo.1990.258.1.E163

98
Kaufman, D. L., Houser, C. R., & Tobin, A. J. (1991). Two forms of the gammaaminobutyric acid synthetic enzyme glutamate decarboxylase have distinct
intraneuronal distributions and cofactor interactions. Journal of Neurochemistry,
56(2), 720–723.
Kaupmann, K., Malitschek, B., Schuler, V., Heid, J., Froestl, W., Beck, P., … Bettler, B.
(1998). GABA(B)-receptor subtypes assemble into functional heteromeric
complexes. Nature, 396(6712), 683–687. https://doi.org/10.1038/25360
Khazaeipool, Z., Wiederman, M., & Inoue, W. (2018). Prostaglandin E2 depresses GABA
release onto parvocellular neuroendocrine neurones in the paraventricular nucleus of
the hypothalamus via presynaptic receptors. Journal of Neuroendocrinology, 30(11),
e12638. https://doi.org/10.1111/jne.12638
Korn, H., & Faber, D. S. (1991). Quantal analysis and synaptic efficacy in the CNS. Trends
in Neurosciences, 14(10), 439–445.
Kotas, M. E., & Medzhitov, R. (2015). Homeostasis, inflammation, and disease
susceptibility. Cell, 160(5), 816–827. https://doi.org/10.1016/j.cell.2015.02.010
Layé, S., Parnet, P., Goujon, E., & Dantzer, R. (1994). Peripheral administration of
lipopolysaccharide induces the expression of cytokine transcripts in the brain and
pituitary of mice. Brain Research. Molecular Brain Research, 27(1), 157–162.
Lechan, R. M., & Fekete, C. (2006). The TRH neuron: a hypothalamic integrator of energy
metabolism. In A. Kalsbeek, E. Fliers, M. A. Hofman, D. F. Swaab, E. J. W. van
Someren, & R. M. Buijs (Eds.), Progress in Brain Research (pp. 209–235).
https://doi.org/10.1016/S0079-6123(06)53012-2

99
Leng, G., Brown, C. H., & Russell, J. A. (1999). Physiological pathways regulating the
activity of magnocellular neurosecretory cells. Progress in Neurobiology, 57(6), 625–
655. https://doi.org/10.1016/S0301-0082(98)00072-0
Li, H. Y., Ericsson, A., & Sawchenko, P. E. (1996). Distinct mechanisms underlie activation
of hypothalamic neurosecretory neurons and their medullary catecholaminergic
afferents in categorically different stress paradigms. Proceedings of the National
Academy of Sciences of the United States of America, 93(6), 2359–2364.
Liposits, Z. (1993). Ultrastructure of hypothalamic paraventricular neurons. Critical Reviews
in Neurobiology, 7(2), 89–162.
Lupien, S. J., Maheu, F., Tu, M., Fiocco, A., & Schramek, T. E. (2007). The effects of stress
and stress hormones on human cognition: Implications for the field of brain and
cognition. Brain and Cognition, 65(3), 209–237.
https://doi.org/10.1016/j.bandc.2007.02.007
Luscher, B., Fuchs, T., & Kilpatrick, C. L. (2011). GABAA receptor trafficking-mediated
plasticity of inhibitory synapses. Neuron, 70(3), 385–409.
https://doi.org/10.1016/j.neuron.2011.03.024
Luther, J. A., Daftary, S. S., Boudaba, C., Gould, G. C., Halmos, K. C., & Tasker, J. G.
(2002). Neurosecretory and Non-Neurosecretory Parvocellular Neurones of the
Hypothalamic Paraventricular Nucleus Express Distinct Electrophysiological
Properties. Journal of Neuroendocrinology, 14(12), 929–932.
https://doi.org/10.1046/j.1365-2826.2002.00867.x
Luther, J. A., Halmos, K. C., & Tasker, J. G. (2000). A slow transient potassium current
expressed in a subset of neurosecretory neurons of the hypothalamic paraventricular

100
nucleus. Journal of Neurophysiology, 84(4), 1814–1825.
https://doi.org/10.1152/jn.2000.84.4.1814
Luther, Jason A., & Tasker, J. G. (2000). Voltage-gated currents distinguish parvocellular
from magnocellular neurones in the rat hypothalamic paraventricular nucleus. The
Journal of Physiology, 523(1), 193–209. https://doi.org/10.1111/j.14697793.2000.t01-1-00193.x
Makara, G. B., & Stark, E. (1974). Effects of gamma-aminobutyric acid (GABA) and GABA
antagonist drugs on ACTH release. Neuroendocrinology, 16(3–4), 178–190.
https://doi.org/10.1159/000122564
Matsuoka, Y., Furuyashiki, T., Bito, H., Ushikubi, F., Tanaka, Y., Kobayashi, T., …
Narumiya, S. (2003). Impaired adrenocorticotropic hormone response to bacterial
endotoxin in mice deficient in prostaglandin E receptor EP1 and EP3 subtypes.
Proceedings of the National Academy of Sciences of the United States of America,
100(7), 4132–4137. https://doi.org/10.1073/pnas.0633341100
Maubach, K., Davis, R., Clark, D., Fenton, G., Lockey, P., Clark, K., … Coleman, R. (2009).
BGC20-1531, a novel, potent and selective prostanoid EP4 receptor antagonist: a
putative new treatment for migraine headache. British Journal of Pharmacology,
156(2), 316–327. https://doi.org/10.1111/j.1476-5381.2009.00027.x
Medzhitov, R., & Janeway, C. (2000). Innate immunity. The New England Journal of
Medicine, 343(5), 338–344. https://doi.org/10.1056/NEJM200008033430506
Miklós, I. H., & Kovács, K. J. (2002). GABAergic innervation of corticotropin-releasing
hormone (CRH)-secreting parvocellular neurons and its plasticity as demonstrated by
quantitative immunoelectron microscopy. Neuroscience, 113(3), 581–592.

101
Morimoto, A., Murakami, N., Nakamori, T., Sakata, Y., & Watanabe, T. (1989). Possible
involvement of prostaglandin E in development of ACTH response in rats induced by
human recombinant interleukin-1. The Journal of Physiology, 411, 245–256.
Müller, M. B., Landgraf, R., Preil, J., Sillaber, I., Kresse, A. E., Keck, M. E., … Wurst, W.
(2000). Selective activation of the hypothalamic vasopressinergic system in mice
deficient for the corticotropin-releasing hormone receptor 1 is dependent on
glucocorticoids. Endocrinology, 141(11), 4262–4269.
https://doi.org/10.1210/endo.141.11.7767
Nabekura, J., Ueno, T., Okabe, A., Furuta, A., Iwaki, T., Shimizu-Okabe, C., … Akaike, N.
(2002). Reduction of KCC2 expression and GABAA receptor-mediated excitation
after in vivo axonal injury. The Journal of Neuroscience: The Official Journal of the
Society for Neuroscience, 22(11), 4412–4417. https://doi.org/20026453
Nakamura, K., Kaneko, T., Yamashita, Y., Hasegawa, H., Katoh, H., & Negishi, M. (2000).
Immunohistochemical localization of prostaglandin EP3 receptor in the rat nervous
system. The Journal of Comparative Neurology, 421(4), 543–569.
Narumiya, S., & Furuyashiki, T. (2011). Fever, inflammation, pain and beyond: prostanoid
receptor research during these 25 years. FASEB Journal: Official Publication of the
Federation of American Societies for Experimental Biology, 25(3), 813–818.
https://doi.org/10.1096/fj.11-0302ufm
Narumiya, S., Sugimoto, Y., & Ushikubi, F. (1999). Prostanoid Receptors: Structures,
Properties, and Functions. Physiological Reviews, 79(4), 1193–1226.
https://doi.org/10.1152/physrev.1999.79.4.1193
Nathan, C. (2002). Points of control in inflammation. Nature, 420(6917), 846–852.
https://doi.org/10.1038/nature01320

102
Negishi, M., Harazono, A., Sugimoto, Y., Ichikawa, A., Hazato, A., & Kurozumi, S. (1994).
TEI-3356, a highly selective agonist for the prostaglandin EP3 receptor.
Prostaglandins, 48(5), 275–283. https://doi.org/10.1016/0090-6980(94)90028-0
Newton, K., & Dixit, V. M. (2012). Signaling in Innate Immunity and Inflammation. Cold
Spring Harbor Perspectives in Biology, 4(3).
https://doi.org/10.1101/cshperspect.a006049
Ogawa, T., Mikuni, M., Kuroda, Y., Muneoka, K., Mori, K. J., & Takahashi, K. (1994).
Periodic maternal deprivation alters stress response in adult offspring: Potentiates the
negative feedback regulation of restraint stress-induced adrenocortical response and
reduces the frequencies of open field-induced behaviors. Pharmacology Biochemistry
and Behavior, 49(4), 961–967. https://doi.org/10.1016/0091-3057(94)90250-X
Ohinata, K., Suetsugu, K., Fujiwara, Y., & Yoshikawa, M. (2006). Activation of
prostaglandin E receptor EP4 subtype suppresses food intake in mice. Prostaglandins
& Other Lipid Mediators, 81(1–2), 31–36.
https://doi.org/10.1016/j.prostaglandins.2006.06.008
Oka, T., Oka, K., Scammell, T. E., Lee, C., Kelly, J. F., Nantel, F., … Saper, C. B. (2000).
Relationship of EP(1-4) prostaglandin receptors with rat hypothalamic cell groups
involved in lipopolysaccharide fever responses. The Journal of Comparative
Neurology, 428(1), 20–32.
Olsen, R. W., & DeLorey, T. M. (1999). GABA Receptor Physiology and Pharmacology.
Basic Neurochemistry: Molecular, Cellular and Medical Aspects. 6th Edition.
Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK28090/

103
Olsen, R. W., & Sieghart, W. (2009). GABA A receptors: subtypes provide diversity of
function and pharmacology. Neuropharmacology, 56(1), 141–148.
https://doi.org/10.1016/j.neuropharm.2008.07.045
Owens, D. F., Boyce, L. H., Davis, M. B. E., & Kriegstein, A. R. (1996). Excitatory GABA
Responses in Embryonic and Neonatal Cortical Slices Demonstrated by Gramicidin
Perforated-Patch Recordings and Calcium Imaging. Journal of Neuroscience, 16(20),
6414–6423. https://doi.org/10.1523/JNEUROSCI.16-20-06414.1996
Pammer, C., Fodor, M., & Palkovits, M. (1988). Localization of corticotropin-releasing
factor, somatostatin, and vasoactive intestinal polypeptide in the parabrachial nuclei
of the human brain. Journal of Neuroscience Research, 20(1), 109–114.
https://doi.org/10.1002/jnr.490200115
Parsadaniantz, S. M., Lebeau, A., Duval, P., Grimaldi, B., Terlain, B., & Kerdelhué, B.
(2000). Effects of the inhibition of cyclo-oxygenase 1 or 2 or 5-lipoxygenase on the
activation of the hypothalamic-pituitary-adrenal axis induced by interleukin-1beta in
the male Rat. Journal of Neuroendocrinology, 12(8), 766–773.
Pathak, H. R., Weissinger, F., Terunuma, M., Carlson, G. C., Hsu, F.-C., Moss, S. J., &
Coulter, D. A. (2007). Disrupted dentate granule cell chloride regulation enhances
synaptic excitability during development of temporal lobe epilepsy. The Journal of
Neuroscience: The Official Journal of the Society for Neuroscience, 27(51), 14012–
14022. https://doi.org/10.1523/JNEUROSCI.4390-07.2007
Pervanidou, P., & Chrousos, G. P. (2010). Chapter 5 - Neuroendocrinology of PostTraumatic Stress Disorder. In L. Martini (Ed.), Progress in Brain Research (pp. 149–
160). https://doi.org/10.1016/S0079-6123(10)82005-9

104
Piekut, D. T., Pretel, S., & Applegate, C. D. (1996). Activation of oxytocin-containing
neurons of the paraventricular nucleus (PVN) following generalized seizures.
Synapse, 23(4), 312–320. https://doi.org/10.1002/(SICI)10982396(199608)23:4<312::AID-SYN9>3.0.CO;2-A
Prasanna, G., Carreiro, S., Anderson, S., Gukasyan, H., Sartnurak, S., Younis, H., … Krauss,
A. (2011). Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2)
agonist on intraocular pressure in preclinical models of glaucoma. Experimental Eye
Research, 93(3), 256–264. https://doi.org/10.1016/j.exer.2011.02.015
Price, D. D. (2000). Psychological and neural mechanisms of the affective dimension of pain.
Science (New York, N.Y.), 288(5472), 1769–1772.
Pruessner, J. C., Dedovic, K., Pruessner, M., Lord, C., Buss, C., Collins, L., … Lupien, S. J.
(2010). Stress regulation in the central nervous system: evidence from structural and
functional neuroimaging studies in human populations - 2008 Curt Richter Award
Winner. Psychoneuroendocrinology, 35(1), 179–191.
https://doi.org/10.1016/j.psyneuen.2009.02.016
Pyter, L. M., Pineros, V., Galang, J. A., McClintock, M. K., & Prendergast, B. J. (2009).
Peripheral tumors induce depressive-like behaviors and cytokine production and alter
hypothalamic-pituitary-adrenal axis regulation. Proceedings of the National Academy
of Sciences of the United States of America, 106(22), 9069–9074.
https://doi.org/10.1073/pnas.0811949106
Quan, N., Stern, E. L., Whiteside, M. B., & Herkenham, M. (1999). Induction of proinflammatory cytokine mRNAs in the brain after peripheral injection of subseptic
doses of lipopolysaccharide in the rat. Journal of Neuroimmunology, 93(1–2), 72–80.

105
Quan, N., Whiteside, M., & Herkenham, M. (1998). Cyclooxygenase 2 mRNA expression in
rat brain after peripheral injection of lipopolysaccharide. Brain Research, 802(1–2),
189–197. https://doi.org/10.1016/S0006-8993(98)00402-8
Ransohoff, R. M., Kivisäkk, P., & Kidd, G. (2003). Three or more routes for leukocyte
migration into the central nervous system. Nature Reviews. Immunology, 3(7), 569–
581. https://doi.org/10.1038/nri1130
Renaud, L. P., & Bourquet, C. W. (1991). Neurophysiology and neuropharmacology of
hypothalamic magnocellular neurons secreting vasopressin and oxytocin. Progress in
Neurobiology, 36(2), 131–169. https://doi.org/10.1016/0301-0082(91)90020-2
Reul, J. M., & de Kloet, E. R. (1985). Two receptor systems for corticosterone in rat brain:
microdistribution and differential occupation. Endocrinology, 117(6), 2505–2511.
https://doi.org/10.1210/endo-117-6-2505
Riazi, K., Galic, M. A., Kuzmiski, J. B., Ho, W., Sharkey, K. A., & Pittman, Q. J. (2008).
Microglial activation and TNFalpha production mediate altered CNS excitability
following peripheral inflammation. Proceedings of the National Academy of Sciences
of the United States of America, 105(44), 17151–17156.
https://doi.org/10.1073/pnas.0806682105
Ricciotti, E., & FitzGerald, G. A. (2011). Prostaglandins and Inflammation. Arteriosclerosis,
Thrombosis, and Vascular Biology, 31(5), 986–1000.
https://doi.org/10.1161/ATVBAHA.110.207449
Rivier, C., & Vale, W. (1991). Stimulatory effect of interleukin-1 on adrenocorticotropin
secretion in the rat: is it modulated by prostaglandins? Endocrinology, 129(1), 384–
388. https://doi.org/10.1210/endo-129-1-384

106
Roland, B. L., & Sawchenko, P. E. (1993). Local origins of some GABAergic projections to
the paraventricular and supraoptic nuclei of the hypothalamus in the rat. The Journal
of Comparative Neurology, 332(1), 123–143. https://doi.org/10.1002/cne.903320109
Roper, J. A., Craighead, M., O’Carroll, A.-M., & Lolait, S. J. (2010). Attenuated Stress
Response to Acute Restraint and Forced Swimming Stress in Arginine Vasopressin
1b Receptor Subtype (Avpr1b) Receptor Knockout Mice and Wild-Type Mice
Treated with a Novel Avpr1b Receptor Antagonist. Journal of Neuroendocrinology,
22(11), 1173–1180. https://doi.org/10.1111/j.1365-2826.2010.02070.x
Rothwell, N. J., Luheshi, G., & Toulmond, S. (1996). Cytokines and their receptors in the
central nervous system: physiology, pharmacology, and pathology. Pharmacology &
Therapeutics, 69(2), 85–95.
Ruzek, M. C., Pearce, B. D., Miller, A. H., & Biron, C. A. (1999). Endogenous
glucocorticoids protect against cytokine-mediated lethality during viral infection.
Journal of Immunology (Baltimore, Md.: 1950), 162(6), 3527–3533.
Salter, E. W., Sunstrum, J. K., Matovic, S., & Inoue, W. (2018). Chronic stress dampens
excitatory synaptic gain in the paraventricular nucleus of the hypothalamus. The
Journal of Physiology, 596(17), 4157–4172. https://doi.org/10.1113/JP275669
Sapolsky, R. M., Romero, L. M., & Munck, A. U. (2000). How do glucocorticoids influence
stress responses? Integrating permissive, suppressive, stimulatory, and preparative
actions. Endocrine Reviews, 21(1), 55–89. https://doi.org/10.1210/edrv.21.1.0389
Sarkar, J., Wakefield, S., MacKenzie, G., Moss, S. J., & Maguire, J. (2011).
Neurosteroidogenesis is required for the physiological response to stress: role of
neurosteroid-sensitive GABAA receptors. The Journal of Neuroscience: The Official

107
Journal of the Society for Neuroscience, 31(50), 18198–18210.
https://doi.org/10.1523/JNEUROSCI.2560-11.2011
Schiltz, J. C., & Sawchenko, P. E. (2002). Distinct brain vascular cell types manifest
inducible cyclooxygenase expression as a function of the strength and nature of
immune insults. The Journal of Neuroscience: The Official Journal of the Society for
Neuroscience, 22(13), 5606–5618. https://doi.org/20026539
Schiltz, J. C., & Sawchenko, P. E. (2003). Signaling the brain in systemic inflammation: the
role of perivascular cells. Frontiers in Bioscience: A Journal and Virtual Library, 8,
s1321-1329.
Schroeder, S., Wichers, M., Klingmüller, D., Höfer, M., Lehmann, L. E., von Spiegel, T., …
Stüber, F. (2001). The hypothalamic-pituitary-adrenal axis of patients with severe
sepsis: altered response to corticotropin-releasing hormone. Critical Care Medicine,
29(2), 310–316.
Schwabe, L., & Wolf, O. T. (2012). Stress modulates the engagement of multiple memory
systems in classification learning. The Journal of Neuroscience: The Official Journal
of the Society for Neuroscience, 32(32), 11042–11049.
https://doi.org/10.1523/JNEUROSCI.1484-12.2012
Scimemi, A. (2014). Structure, function, and plasticity of GABA transporters. Frontiers in
Cellular Neuroscience, 8. https://doi.org/10.3389/fncel.2014.00161
Senst, L. (2014). Stress, sex and synapses: an exploration of stress-associated male/female
differences in electrophysiological properties of corticotropin-releasing hormone
neurons of the paraventricular nucleus of the hypothalamus.
http://dx.doi.org/10.11575/PRISM/27895

108
Sheikh, S. N., Martin, S. B., & Martin, D. L. (1999). Regional distribution and relative
amounts of glutamate decarboxylase isoforms in rat and mouse brain. Neurochemistry
International, 35(1), 73–80. https://doi.org/10.1016/S0197-0186(99)00063-7
Silverman, M. N., Pearce, B. D., Biron, C. A., & Miller, A. H. (2005). Immune Modulation
of the Hypothalamic-Pituitary-Adrenal (HPA) Axis during Viral Infection. Viral
Immunology, 18(1), 41–78. https://doi.org/10.1089/vim.2005.18.41
Simmons, D. M., & Swanson, L. W. (2009). Comparison of the spatial distribution of seven
types of neuroendocrine neurons in the rat paraventricular nucleus: toward a global
3D model. The Journal of Comparative Neurology, 516(5), 423–441.
https://doi.org/10.1002/cne.22126
Smith, S. M., & Vale, W. W. (2006). The role of the hypothalamic-pituitary-adrenal axis in
neuroendocrine responses to stress. Dialogues in Clinical Neuroscience, 8(4), 383–
395.
Somogyi, P., Tamás, G., Lujan, R., & Buhl, E. H. (1998). Salient features of synaptic
organisation in the cerebral cortex. Brain Research. Brain Research Reviews, 26(2–
3), 113–135.
Stalla, G. K., Stalla, J., Loeffler, J. P., von Werder, K., & Müller, O. A. (1987).
Pharmacological modulation of CRH-stimulated ACTH secretion by ketoconazole.
Hormone and Metabolic Research. Supplement Series, 16, 31–36.
Stern, J. E. (2001). Electrophysiological and morphological properties of pre-autonomic
neurones in the rat hypothalamic paraventricular nucleus. The Journal of Physiology,
537(Pt 1), 161–177. https://doi.org/10.1111/j.1469-7793.2001.0161k.x

109
Stern, J. E. (2015). Neuroendocrine-autonomic integration in the paraventricular nucleus:
novel roles for dendritically released neuropeptides. Journal of Neuroendocrinology,
27(6), 487–497. https://doi.org/10.1111/jne.12252
Südhof, T. C. (2012). Calcium Control of Neurotransmitter Release. Cold Spring Harbor
Perspectives in Biology, 4(1). https://doi.org/10.1101/cshperspect.a011353
Sugimoto, Y., & Narumiya, S. (2007). Prostaglandin E receptors. The Journal of Biological
Chemistry, 282(16), 11613–11617. https://doi.org/10.1074/jbc.R600038200
Swanson, L. W., & Kuypers, H. G. (1980). The paraventricular nucleus of the hypothalamus:
cytoarchitectonic subdivisions and organization of projections to the pituitary, dorsal
vagal complex, and spinal cord as demonstrated by retrograde fluorescence doublelabeling methods. The Journal of Comparative Neurology, 194(3), 555–570.
https://doi.org/10.1002/cne.901940306
Swanson, L. W., & Sawchenko, P. E. (1983). Hypothalamic integration: organization of the
paraventricular and supraoptic nuclei. Annual Review of Neuroscience, 6, 269–324.
https://doi.org/10.1146/annurev.ne.06.030183.001413
Swanson, L. W., Sawchenko, P. E., Rivier, J., & Vale, W. W. (1983). Organization of ovine
corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an
immunohistochemical study. Neuroendocrinology, 36(3), 165–186.
https://doi.org/10.1159/000123454
Tao, Y.-H., Yuan, Z., Tang, X.-Q., Xu, H.-B., & Yang, X.-L. (2006). Inhibition of GABA
shunt enzymes’ activity by 4-hydroxybenzaldehyde derivatives. Bioorganic &
Medicinal Chemistry Letters, 16(3), 592–595.
https://doi.org/10.1016/j.bmcl.2005.10.040

110
Tasker, J G, & Dudek, F. E. (1991). Electrophysiological properties of neurones in the region
of the paraventricular nucleus in slices of rat hypothalamus. The Journal of
Physiology, 434(1), 271–293. https://doi.org/10.1113/jphysiol.1991.sp018469
Tasker, Jeffrey G., & Herman, J. P. (2011). Mechanisms of rapid glucocorticoid feedback
inhibition of the hypothalamic-pituitary-adrenal axis. Stress (Amsterdam,
Netherlands), 14(4), 398–406. https://doi.org/10.3109/10253890.2011.586446
Tsumori, C., Shibasaki, T., Hotta, M., Takeuchi, K., Yamauchi, N., Imaki, T., … Demura, H.
(1998). Interleukin-1beta administered intracerebroventricularly stimulates the release
of noradrenaline in the hypothalamic paraventricular nucleus via prostaglandin in the
rat. Endocrine Journal, 45(1), 127–130.
Turrin, N. P., Gayle, D., Ilyin, S. E., Flynn, M. C., Langhans, W., Schwartz, G. J., & PlataSalamán, C. R. (2001). Pro-inflammatory and anti-inflammatory cytokine mRNA
induction in the periphery and brain following intraperitoneal administration of
bacterial lipopolysaccharide. Brain Research Bulletin, 54(4), 443–453.
Ulrich-Lai, Y. M., & Herman, J. P. (2009). Neural regulation of endocrine and autonomic
stress responses. Nature Reviews. Neuroscience, 10(6), 397–409.
https://doi.org/10.1038/nrn2647
Unger, R. H., Dobbs, R. E., & Orci, L. (1978). Insulin, Glucagon, and Somatostatin Secretion
in the Regulation of Metabolism. Annual Review of Physiology, 40(1), 307–343.
https://doi.org/10.1146/annurev.ph.40.030178.001515
Vale, W., Spiess, J., Rivier, C., & Rivier, J. (1981). Characterization of a 41-residue ovine
hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin.
Science (New York, N.Y.), 213(4514), 1394–1397.

111
van Haarst, A. D., Oitzl, M. S., & de Kloet, E. R. (1997). Facilitation of Feedback Inhibition
Through Blockade of Glucocorticoid Receptors in the Hippocampus. Neurochemical
Research, 22(11), 1323–1328. https://doi.org/10.1023/A:1022010904600
Verkuyl, J. M., Hemby, S. E., & Joëls, M. (2004). Chronic stress attenuates GABAergic
inhibition and alters gene expression of parvocellular neurons in rat hypothalamus.
The European Journal of Neuroscience, 20(6), 1665–1673.
https://doi.org/10.1111/j.1460-9568.2004.03568.x
Watanabe, M., Maemura, K., Kanbara, K., Tamayama, T., & Hayasaki, H. (2002). GABA
and GABA receptors in the central nervous system and other organs. International
Review of Cytology, 213, 1–47.
Woodward, D. F., Jones, R. L., & Narumiya, S. (2011). International Union of Basic and
Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15
years of progress. Pharmacological Reviews, 63(3), 471–538.
https://doi.org/10.1124/pr.110.003517
Wotjak, C. T., Ganster, J., Kohl, G., Holsboer, F., Landgraf, R., & Engelmann, M. (1998).
Dissociated central and peripheral release of vasopressin, but not oxytocin, in
response to repeated swim stress: new insights into the secretory capacities of
peptidergic neurons. Neuroscience, 85(4), 1209–1222.
Wu, C., & Sun, D. (2015). GABA receptors in brain development, function, and injury.
Metabolic Brain Disease, 30(2), 367–379. https://doi.org/10.1007/s11011-014-9560-1
Yamamoto, D., Fukami, J.-I., & Washio, H. (1981). VOltage Clamp Studies on Insect
Skeletal Muscle: I. The Inward Current. Journal of Experimental Biology, 92(1), 1–
12.

112
Yehuda, R., Giller, E. L., Southwick, S. M., Lowy, M. T., & Mason, J. W. (1991).
Hypothalamic-pituitary-adrenal dysfunction in posttraumatic stress disorder.
Biological Psychiatry, 30(10), 1031–1048. https://doi.org/10.1016/00063223(91)90123-4
Young, R., Billot, X., Han, Y., A. Slipetz, D., Chauret, N., Belley, M., … Girard, M. (2004).
Discovery and Synthesis of a Potent, Selective and Orally Bioavailable EP4 Receptor
Agonist. Heterocycles, 64, 437–446. https://doi.org/10.3987/COM-04-S(P)47
Yuen, E. Y., Liu, W., Karatsoreos, I. N., Feng, J., McEwen, B. S., & Yan, Z. (2009). Acute
stress enhances glutamatergic transmission in prefrontal cortex and facilitates
working memory. Proceedings of the National Academy of Sciences of the United
States of America, 106(33), 14075–14079. https://doi.org/10.1073/pnas.0906791106
Zhang, J., & Rivest, S. (1999). Distribution, regulation and colocalization of the genes
encoding the EP2- and EP4-PGE2 receptors in the rat brain and neuronal responses to
systemic inflammation. The European Journal of Neuroscience, 11(8), 2651–2668.
Zhang, J., & Rivest, S. (2000). A functional analysis of EP4 receptor-expressing neurons in
mediating the action of prostaglandin E2 within specific nuclei of the brain in
response to circulating interleukin-1beta. Journal of Neurochemistry, 74(5), 2134–
2145.
Zhang, Z.-H., Yu, Y., Wei, S.-G., Nakamura, Y., Nakamura, K., & Felder, R. B. (2011). EP3
receptors mediate PGE2-induced hypothalamic paraventricular nucleus excitation and
sympathetic activation. American Journal of Physiology - Heart and Circulatory
Physiology, 301(4), H1559–H1569. https://doi.org/10.1152/ajpheart.00262.2011
Zimprich, A., Garrett, L., Deussing, J. M., Wotjak, C. T., Fuchs, H., Gailus-Durner, V., …
Hölter, S. M. (2014). A robust and reliable non-invasive test for stress responsivity in

113
mice. Frontiers in Behavioral Neuroscience, 8.
https://doi.org/10.3389/fnbeh.2014.00125
Zucker, R. S., & Regehr, W. G. (2002). Short-term synaptic plasticity. Annual Review of
Physiology, 64, 355–405. https://doi.org/10.1146/annurev.physiol.64.092501.114547

114

Appendices
Appendix A: Rights for Figure 1-3.
JOHN WILEY AND SONS LICENSE
TERMS AND CONDITIONS
Jun 28, 2019

This Agreement between Ms. Meagan Wiederman ("You") and John Wiley and Sons
("John Wiley and Sons") consists of your license details and the terms and conditions
provided by John Wiley and Sons and Copyright Clearance Center.
License Number

4612071020050

License date

Jun 18, 2019

Licensed Content Publisher

John Wiley and Sons

Licensed Content Publication

Journal of Comparative Neurology

Licensed Content Title

Comparison of the spatial distribution of seven types
of neuroendocrine neurons in the rat paraventricular
nucleus: Toward a global 3D model

Licensed Content Author

Donna M. Simmons, Larry W. Swanson

Licensed Content Date

Aug 5, 2009

Licensed Content Volume

516

Licensed Content Issue

5

Licensed Content Pages

19

Type of use

Dissertation/Thesis

Requestor type

University/Academic

Format

Print and electronic

Portion

Figure/table

Number of figures/tables

1

Original Wiley figure/table number(s)

Figure 5 section on p. 433 of 25.5a

Will you be translating?

No

Order reference number

153

Title of your thesis / dissertation

Psychological stress modulates synaptic mechanisms
for prostaglandin E2-mediated HPA axis activation

Expected completion date

Jun 2019

Expected size (number of pages)

1

Requestor Location

Ms. Meagan Wiederman
[redacted]
Attn: Ms. Meagan Wiederman

Publisher Tax ID

EU826007151

Total

0.00 CAD

115
Terms and Conditions

TERMS AND CONDITIONS
This copyrighted material is owned by or exclusively licensed to John Wiley & Sons, Inc.
or one of its group companies (each a"Wiley Company") or handled on behalf of a society
with which a Wiley Company has exclusive publishing rights in relation to a particular
work (collectively "WILEY"). By clicking "accept" in connection with completing this
licensing transaction, you agree that the following terms and conditions apply to this
transaction (along with the billing and payment terms and conditions established by the
Copyright Clearance Center Inc., ("CCC's Billing and Payment terms and conditions"), at
the time that you opened your RightsLink account (these are available at any time
at http://myaccount.copyright.com).
Terms and Conditions
•

The materials you have requested permission to reproduce or reuse (the "Wiley
Materials") are protected by copyright.

•

You are hereby granted a personal, non-exclusive, non-sub licensable (on a standalone basis), non-transferable, worldwide, limited license to reproduce the Wiley
Materials for the purpose specified in the licensing process. This license, and any
CONTENT (PDF or image file) purchased as part of your order, is for a onetime use only and limited to any maximum distribution number specified in the
license. The first instance of republication or reuse granted by this license must be
completed within two years of the date of the grant of this license (although copies
prepared before the end date may be distributed thereafter). The Wiley Materials
shall not be used in any other manner or for any other purpose, beyond what is
granted in the license. Permission is granted subject to an appropriate
acknowledgement given to the author, title of the material/book/journal and the
publisher. You shall also duplicate the copyright notice that appears in the Wiley
publication in your use of the Wiley Material. Permission is also granted on the
understanding that nowhere in the text is a previously published source
acknowledged for all or part of this Wiley Material. Any third party content is
expressly excluded from this permission.

•

With respect to the Wiley Materials, all rights are reserved. Except as expressly
granted by the terms of the license, no part of the Wiley Materials may be copied,
modified, adapted (except for minor reformatting required by the new Publication),
translated, reproduced, transferred or distributed, in any form or by any means, and
no derivative works may be made based on the Wiley Materials without the prior
permission of the respective copyright owner.For STM Signatory Publishers
clearing permission under the terms of the STM Permissions Guidelines only,
the terms of the license are extended to include subsequent editions and for
editions in other languages, provided such editions are for the work as a whole
in situ and does not involve the separate exploitation of the permitted figures or
extracts,You may not alter, remove or suppress in any manner any copyright,
trademark or other notices displayed by the Wiley Materials. You may not license,
rent, sell, loan, lease, pledge, offer as security, transfer or assign the Wiley Materials

116
on a stand-alone basis, or any of the rights granted to you hereunder to any other
person.
•

The Wiley Materials and all of the intellectual property rights therein shall at all
times remain the exclusive property of John Wiley & Sons Inc, the Wiley
Companies, or their respective licensors, and your interest therein is only that of
having possession of and the right to reproduce the Wiley Materials pursuant to
Section 2 herein during the continuance of this Agreement. You agree that you own
no right, title or interest in or to the Wiley Materials or any of the intellectual
property rights therein. You shall have no rights hereunder other than the license as
provided for above in Section 2. No right, license or interest to any trademark, trade
name, service mark or other branding ("Marks") of WILEY or its licensors is
granted hereunder, and you agree that you shall not assert any such right, license or
interest with respect thereto

•

NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR
REPRESENTATION OF ANY KIND TO YOU OR ANY THIRD PARTY,
EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE
MATERIALS OR THE ACCURACY OF ANY INFORMATION CONTAINED IN
THE MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED
WARRANTY OF MERCHANTABILITY, ACCURACY, SATISFACTORY
QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY,
INTEGRATION OR NON-INFRINGEMENT AND ALL SUCH WARRANTIES
ARE HEREBY EXCLUDED BY WILEY AND ITS LICENSORS AND WAIVED
BY YOU.

•

WILEY shall have the right to terminate this Agreement immediately upon breach
of this Agreement by you.

•

You shall indemnify, defend and hold harmless WILEY, its Licensors and their
respective directors, officers, agents and employees, from and against any actual or
threatened claims, demands, causes of action or proceedings arising from any breach
of this Agreement by you.

•

IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR
ANY OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY
SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR
PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN
CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING OR
USE OF THE MATERIALS REGARDLESS OF THE FORM OF ACTION,
WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY,
TORT, NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING,
WITHOUT LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA,
FILES, USE, BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES),
AND WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF THE
POSSIBILITY OF SUCH DAMAGES. THIS LIMITATION SHALL APPLY

117
NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY
LIMITED REMEDY PROVIDED HEREIN.
•

Should any provision of this Agreement be held by a court of competent jurisdiction
to be illegal, invalid, or unenforceable, that provision shall be deemed amended to
achieve as nearly as possible the same economic effect as the original provision, and
the legality, validity and enforceability of the remaining provisions of this
Agreement shall not be affected or impaired thereby.

•

The failure of either party to enforce any term or condition of this Agreement shall
not constitute a waiver of either party's right to enforce each and every term and
condition of this Agreement. No breach under this agreement shall be deemed
waived or excused by either party unless such waiver or consent is in writing signed
by the party granting such waiver or consent. The waiver by or consent of a party to
a breach of any provision of this Agreement shall not operate or be construed as a
waiver of or consent to any other or subsequent breach by such other party.

•

This Agreement may not be assigned (including by operation of law or otherwise)
by you without WILEY's prior written consent.

•

Any fee required for this permission shall be non-refundable after thirty (30) days
from receipt by the CCC.

•

These terms and conditions together with CCC's Billing and Payment terms and
conditions (which are incorporated herein) form the entire agreement between you
and WILEY concerning this licensing transaction and (in the absence of fraud)
supersedes all prior agreements and representations of the parties, oral or written.
This Agreement may not be amended except in writing signed by both parties. This
Agreement shall be binding upon and inure to the benefit of the parties' successors,
legal representatives, and authorized assigns.

•

In the event of any conflict between your obligations established by these terms and
conditions and those established by CCC's Billing and Payment terms and
conditions, these terms and conditions shall prevail.

•

WILEY expressly reserves all rights not specifically granted in the combination of
(i) the license details provided by you and accepted in the course of this licensing
transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment
terms and conditions.

•

This Agreement will be void if the Type of Use, Format, Circulation, or Requestor
Type was misrepresented during the licensing process.

•

This Agreement shall be governed by and construed in accordance with the laws of
the State of New York, USA, without regards to such state's conflict of law rules.
Any legal action, suit or proceeding arising out of or relating to these Terms and
Conditions or the breach thereof shall be instituted in a court of competent
jurisdiction in New York County in the State of New York in the United States of

118
America and each party hereby consents and submits to the personal jurisdiction of
such court, waives any objection to venue in such court and consents to service of
process by registered or certified mail, return receipt requested, at the last known
address of such party.
WILEY OPEN ACCESS TERMS AND CONDITIONS
Wiley Publishes Open Access Articles in fully Open Access Journals and in Subscription
journals offering Online Open. Although most of the fully Open Access journals publish
open access articles under the terms of the Creative Commons Attribution (CC BY) License
only, the subscription journals and a few of the Open Access Journals offer a choice of
Creative Commons Licenses. The license type is clearly identified on the article.
The Creative Commons Attribution License
The Creative Commons Attribution License (CC-BY) allows users to copy, distribute and
transmit an article, adapt the article and make commercial use of the article. The CC-BY
license permits commercial and nonCreative Commons Attribution Non-Commercial License
The Creative Commons Attribution Non-Commercial (CC-BY-NC)License permits use,
distribution and reproduction in any medium, provided the original work is properly cited
and is not used for commercial purposes.(see below)
Creative Commons Attribution-Non-Commercial-NoDerivs License
The Creative Commons Attribution Non-Commercial-NoDerivs License (CC-BY-NC-ND)
permits use, distribution and reproduction in any medium, provided the original work is
properly cited, is not used for commercial purposes and no modifications or adaptations are
made. (see below)
Use by commercial "for-profit" organizations
Use of Wiley Open Access articles for commercial, promotional, or marketing purposes
requires further explicit permission from Wiley and will be subject to a fee.
Further details can be found on Wiley Online
Library http://olabout.wiley.com/WileyCDA/Section/id-410895.html

Other Terms and Conditions:

v1.10 Last updated September 2015
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.

119
Appendix B: Rights for Figure 1-5.
JOHN WILEY AND SONS LICENSE
TERMS AND CONDITIONS
Jun 28, 2019

This Agreement between Ms. Meagan Wiederman ("You") and John Wiley and Sons
("John Wiley and Sons") consists of your license details and the terms and conditions
provided by John Wiley and Sons and Copyright Clearance Center.
License Number

4612070627292

License date

Jun 18, 2019

Licensed Content Publisher

John Wiley and Sons

Licensed Content Publication

Journal of Physiology

Licensed Content Title

Voltage‐gated currents distinguish parvocellular from
magnocellular neurones in the rat hypothalamic
paraventricular nucleus

Licensed Content Author

Jason A. Luther, Jeffrey G. Tasker

Licensed Content Date

Aug 13, 2004

Licensed Content Volume

523

Licensed Content Issue

1

Licensed Content Pages

17

Type of use

Dissertation/Thesis

Requestor type

University/Academic

Format

Print and electronic

Portion

Figure/table

Number of figures/tables

1

Original Wiley figure/table number(s)

Figure 1

Will you be translating?

No

Order reference number

101

Title of your thesis / dissertation

Psychological stress modulates synaptic mechanisms for
prostaglandin E2-mediated HPA axis activation

Expected completion date

Jun 2019

Expected size (number of pages)

1

Requestor Location

Ms. Meagan Wiederman
[redacted]
Attn: Ms. Meagan Wiederman

Publisher Tax ID

EU826007151

Total

0.0 CAD

Terms and Conditions

120
TERMS AND CONDITIONS
This copyrighted material is owned by or exclusively licensed to John Wiley & Sons, Inc.
or one of its group companies (each a"Wiley Company") or handled on behalf of a society
with which a Wiley Company has exclusive publishing rights in relation to a particular
work (collectively "WILEY"). By clicking "accept" in connection with completing this
licensing transaction, you agree that the following terms and conditions apply to this
transaction (along with the billing and payment terms and conditions established by the
Copyright Clearance Center Inc., ("CCC's Billing and Payment terms and conditions"), at
the time that you opened your RightsLink account (these are available at any time
at http://myaccount.copyright.com).
Terms and Conditions
•

The materials you have requested permission to reproduce or reuse (the "Wiley
Materials") are protected by copyright.

•

You are hereby granted a personal, non-exclusive, non-sub licensable (on a standalone basis), non-transferable, worldwide, limited license to reproduce the Wiley
Materials for the purpose specified in the licensing process. This license, and any
CONTENT (PDF or image file) purchased as part of your order, is for a onetime use only and limited to any maximum distribution number specified in the
license. The first instance of republication or reuse granted by this license must be
completed within two years of the date of the grant of this license (although copies
prepared before the end date may be distributed thereafter). The Wiley Materials
shall not be used in any other manner or for any other purpose, beyond what is
granted in the license. Permission is granted subject to an appropriate
acknowledgement given to the author, title of the material/book/journal and the
publisher. You shall also duplicate the copyright notice that appears in the Wiley
publication in your use of the Wiley Material. Permission is also granted on the
understanding that nowhere in the text is a previously published source
acknowledged for all or part of this Wiley Material. Any third party content is
expressly excluded from this permission.

•

With respect to the Wiley Materials, all rights are reserved. Except as expressly
granted by the terms of the license, no part of the Wiley Materials may be copied,
modified, adapted (except for minor reformatting required by the new Publication),
translated, reproduced, transferred or distributed, in any form or by any means, and
no derivative works may be made based on the Wiley Materials without the prior
permission of the respective copyright owner.For STM Signatory Publishers
clearing permission under the terms of the STM Permissions Guidelines only,
the terms of the license are extended to include subsequent editions and for
editions in other languages, provided such editions are for the work as a whole
in situ and does not involve the separate exploitation of the permitted figures or
extracts,You may not alter, remove or suppress in any manner any copyright,
trademark or other notices displayed by the Wiley Materials. You may not license,
rent, sell, loan, lease, pledge, offer as security, transfer or assign the Wiley Materials

121
on a stand-alone basis, or any of the rights granted to you hereunder to any other
person.
•

The Wiley Materials and all of the intellectual property rights therein shall at all
times remain the exclusive property of John Wiley & Sons Inc, the Wiley
Companies, or their respective licensors, and your interest therein is only that of
having possession of and the right to reproduce the Wiley Materials pursuant to
Section 2 herein during the continuance of this Agreement. You agree that you own
no right, title or interest in or to the Wiley Materials or any of the intellectual
property rights therein. You shall have no rights hereunder other than the license as
provided for above in Section 2. No right, license or interest to any trademark, trade
name, service mark or other branding ("Marks") of WILEY or its licensors is
granted hereunder, and you agree that you shall not assert any such right, license or
interest with respect thereto

•

NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR
REPRESENTATION OF ANY KIND TO YOU OR ANY THIRD PARTY,
EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE
MATERIALS OR THE ACCURACY OF ANY INFORMATION CONTAINED
IN THE MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED
WARRANTY OF MERCHANTABILITY, ACCURACY, SATISFACTORY
QUALITY, FITNESS FOR A PARTICULAR PURPOSE, USABILITY,
INTEGRATION OR NON-INFRINGEMENT AND ALL SUCH WARRANTIES
ARE HEREBY EXCLUDED BY WILEY AND ITS LICENSORS AND WAIVED
BY YOU.

•

WILEY shall have the right to terminate this Agreement immediately upon breach
of this Agreement by you.

•

You shall indemnify, defend and hold harmless WILEY, its Licensors and their
respective directors, officers, agents and employees, from and against any actual or
threatened claims, demands, causes of action or proceedings arising from any
breach of this Agreement by you.

•

IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR
ANY OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY
SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR
PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN
CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING OR
USE OF THE MATERIALS REGARDLESS OF THE FORM OF ACTION,
WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY,
TORT, NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING,
WITHOUT LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA,
FILES, USE, BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES),
AND WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF THE
POSSIBILITY OF SUCH DAMAGES. THIS LIMITATION SHALL APPLY

122
NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY
LIMITED REMEDY PROVIDED HEREIN.
•

Should any provision of this Agreement be held by a court of competent jurisdiction
to be illegal, invalid, or unenforceable, that provision shall be deemed amended to
achieve as nearly as possible the same economic effect as the original provision, and
the legality, validity and enforceability of the remaining provisions of this
Agreement shall not be affected or impaired thereby.

•

The failure of either party to enforce any term or condition of this Agreement shall
not constitute a waiver of either party's right to enforce each and every term and
condition of this Agreement. No breach under this agreement shall be deemed
waived or excused by either party unless such waiver or consent is in writing signed
by the party granting such waiver or consent. The waiver by or consent of a party to
a breach of any provision of this Agreement shall not operate or be construed as a
waiver of or consent to any other or subsequent breach by such other party.

•

This Agreement may not be assigned (including by operation of law or otherwise)
by you without WILEY's prior written consent.

•

Any fee required for this permission shall be non-refundable after thirty (30) days
from receipt by the CCC.

•

These terms and conditions together with CCC's Billing and Payment terms and
conditions (which are incorporated herein) form the entire agreement between you
and WILEY concerning this licensing transaction and (in the absence of fraud)
supersedes all prior agreements and representations of the parties, oral or written.
This Agreement may not be amended except in writing signed by both parties. This
Agreement shall be binding upon and inure to the benefit of the parties' successors,
legal representatives, and authorized assigns.

•

In the event of any conflict between your obligations established by these terms and
conditions and those established by CCC's Billing and Payment terms and
conditions, these terms and conditions shall prevail.

•

WILEY expressly reserves all rights not specifically granted in the combination of
(i) the license details provided by you and accepted in the course of this licensing
transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment
terms and conditions.

•

This Agreement will be void if the Type of Use, Format, Circulation, or Requestor
Type was misrepresented during the licensing process.

•

This Agreement shall be governed by and construed in accordance with the laws of
the State of New York, USA, without regards to such state's conflict of law rules.
Any legal action, suit or proceeding arising out of or relating to these Terms and
Conditions or the breach thereof shall be instituted in a court of competent
jurisdiction in New York County in the State of New York in the United States of

123
America and each party hereby consents and submits to the personal jurisdiction of
such court, waives any objection to venue in such court and consents to service of
process by registered or certified mail, return receipt requested, at the last known
address of such party.
WILEY OPEN ACCESS TERMS AND CONDITIONS
Wiley Publishes Open Access Articles in fully Open Access Journals and in Subscription
journals offering Online Open. Although most of the fully Open Access journals publish
open access articles under the terms of the Creative Commons Attribution (CC BY) License
only, the subscription journals and a few of the Open Access Journals offer a choice of
Creative Commons Licenses. The license type is clearly identified on the article.
The Creative Commons Attribution License
The Creative Commons Attribution License (CC-BY) allows users to copy, distribute and
transmit an article, adapt the article and make commercial use of the article. The CC-BY
license permits commercial and nonCreative Commons Attribution Non-Commercial License
The Creative Commons Attribution Non-Commercial (CC-BY-NC)License permits use,
distribution and reproduction in any medium, provided the original work is properly cited
and is not used for commercial purposes.(see below)
Creative Commons Attribution-Non-Commercial-NoDerivs License
The Creative Commons Attribution Non-Commercial-NoDerivs License (CC-BY-NC-ND)
permits use, distribution and reproduction in any medium, provided the original work is
properly cited, is not used for commercial purposes and no modifications or adaptations are
made. (see below)
Use by commercial "for-profit" organizations
Use of Wiley Open Access articles for commercial, promotional, or marketing purposes
requires further explicit permission from Wiley and will be subject to a fee.
Further details can be found on Wiley Online
Library http://olabout.wiley.com/WileyCDA/Section/id-410895.html

Other Terms and Conditions:

v1.10 Last updated September 2015
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.

124

Curriculum Vitae
Name:

Meagan Wiederman

Post-secondary
Education and
Degrees:

The University of Western Ontario
London, Ontario, Canada
2017-2019 M.Sc. Candidate
Dalhousie University
Halifax, Nova Scotia, Canada
2013-2017 B.Sc.

Honours and
Awards:

Neuroscience Research Day – M.Sc. Poster Award
2019
David and Ruth Hubel Award
2016

Related Work
Experience

Teaching Assistant
The University of Western Ontario
2017-2019
Research Assistant
Dalhousie University
2014-2017

Publications:
Khazaeipool, Z., Wiederman, M. & Inoue, W. (2018). Prostaglandin E2 depresses GABA release onto
parvocellular neuroendocrine neurones in the paraventricular nucleus of the hypothalamus via
presynaptic receptors. Journal of Neuroendocrinology, 30(11), e12638.
doi: 10.1111/jne.12638.
Horne, J. A., Langille, C., McLin, S., Wiederman, M., Lu, Z. Xu, C. S., Plaza, S. M., Scheffer, L. K.,
Hess, H. F., & Meinertzhagen, I. A. (2018). A resource for the Drosophila antennal lobe
provided by the connectome of glomerulus VA1v. eLife, 7, e37550.
doi: 10.7554/eLife.37550.

